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Post-transcriptional Regulation of Myelin Basic Protein Expression 
Anthony William Giampetruzzi, Ph.D. 
University of Connecticut, 2014 
Abstract 
Myelin basic protein (MBP) is essential for the formation of myelin in the central nervous system 
(CNS).  We have examined three factors that can potentially regulate its expression post-
transcriptionally: the fragile X mental retardation protein (FMRP), the fragile X premutation 
transcript, and the tumor overexpressed gene (TOG) protein.  We have revealed the presence 
of FMRP, a known translation inhibitor, in oligodendrocytes (OLGs) but found it had no effect on 
the translation of MBP mRNA.  Correspondingly, the absence of FMRP in the Fmr1 KO mouse 
did not result in increased MBP translation. 
The presence in FXTAS patients of the fragile X premutation transcript, which contains 
expanded CGG repeats, has been associated with myelin changes in the CNS.  We have found 
expanded CGG repeat RNA to be present in RNA granules that contain MBP transcripts.  The 
presence of expanded CGG repeat RNA increased the expression of MBP mRNA in OLGs.  In 
addition, increased translation of microinjected MBP mRNA occurred in fibroblasts from FXTAS 
individuals, suggesting that MBP mRNA translation may be upregulated in FXTAS. 
Knocking out TOG in mouse OLGs results in the near absence of MBP, despite a normal level 
of MBP transcripts, and extensive CNS dysmyelination.  Levels of other myelin proteins, 
proteolipid protein (PLP) and myelin-associated glycoprotein (MAG), were found to be similarly 
reduced.  We have determined that TOG heterozygote (+/null) mice, which express half the 
normal level of TOG, have normal MBP levels before 45 days of age.  This suggests that 
another mechanism, besides the originally proposed decrease in MBP mRNA translation, is the  
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cause of MBP deficiencies in the 90 day old TOG heterozygotes.  TOG is a microtubule-
associated protein and may be necessary for the transport of MBP mRNA granules to the 
myelin compartment where translation occurs.  The effect of the reduction of TOG on 
microtubule based transport was examined by measuring the transport parameters of 
mitochondria in the processes of cultured OLGs.  The transport of mitochondria was only slightly 
altered in the TOG heterozygote.  These results suggest that approximately half the amount of 
TOG allows for sufficient transport and proper translation of MBP mRNA. 
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Chapter 1: Introduction 
 
The myelin membrane which surrounds axons plays a vital role in the nervous system.  In the 
central nervous system (CNS), myelin basic protein is a major component of myelin.  MBP 
expression can be regulated post-transcriptionally. Based on published literature, we examined 
three possible factors involved in the post-transcriptional regulation of MBP expression.  These 
factors are the fragile X mental retardation protein (FMRP), the fragile X premutation RNA 
present in fragile X-associated tremor/ataxia syndrome (FXTAS), and the tumor overexpressed 
gene (TOG) protein.  An overview of these factors, MBP, and myelin is presented in this 
chapter.  Chapters 2-4 provide the results of our examination into the post-transcriptional 
regulation of MBP expression by the three factors.  
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Myelin 
Myelin and Oligodendrocyte Functions 
In the CNS, many axons are surrounded by a multilamellar membrane termed myelin, which is 
produced by oligodendrocytes (OLGs).  Axons are myelinated by multiple OLGs and one OLG 
can myelinate numerous axons, up to approximately 40 (Quarles et al., 2006).  Myelin wrapping 
of an axon facilitates saltatory conduction of action potentials down the axon.  It does so by 
acting as an electrical insulator and leading to the clustering of sodium channels at the 
unmyelinated regions of the axons, known as the Nodes of Ranvier.  The myelin membrane has 
a high lipid to protein ratio (70% to 30%) and low water content (40%), which contributes to its 
ability to be a good insulator.  The thickness of the myelin sheath further improves its ability to 
be an insulator: on average the myelin sheath surrounding axons in the rodent brain stem is 320 
nm (Chomiak and Hu, 2009).  Saltatory conduction is much faster than conduction in non-
myelinated fibers and allows the axon to use less energy and inhabit less space than an 
unmyelinated axon.  For instance, if a myelinated frog axon with a diameter of 12 µm was 
conducting at 25 m/s, an unmyelinated axon of a giant squid would require approximately 
15,000 times the space and 5,000 times the energy to conduct at the identical speed (Quarles 
et al., 2006).   
 
Myelin and OLGs play other roles in support of axons.   Myelination is involved in regulating 
phosphorylation of axonal neurofilaments and expression of axonal cytoskeletal components 
(Brady et al., 1999).  Abnormalities in myelin sheaths cause alterations in axonal microtubules 
and change axonal transport rates (Bradl and Lassmann, 2010).   Myelin also provides 
metabolic support for axons and protects against axonal degeneration (Fünfschilling et al., 
2012; Yin et al., 2006).   For example, lactate and pyruvate are transported from OLGs to 
myelinated axons, and used by axons when energy levels are low (Fünfschilling et al., 2012).  
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Myelin proteins are also involved in the inhibition of axon sprouting (Schwab and Thoenen, 
1985; Dawe et al., 2006).  The proposed role of this is to repress axon sprouting during 
development, therefore inhibiting the formation of new synapses after proper connections have 
been established (Fields, 2008).  These proteins have the same role in preventing axonal 
outgrowth in response to axonal injury (Bregman et al., 1995; McKerracher et.al., 1994).  
Interestingly, OLGs serve functions that support the axon that do not act through myelin.  OLGs 
provide trophic support to axons by synthesizing factors such as glial cell line-derived 
neurotrophic factor (GDNF), insulin-like growth factor 1 (IGF-1), and brain derived neurotrophic 
factor (BDNF) (Smith et al., 2013; Bradl and Lassman, 2010).  Finally, the wrapping of axons by 
OLGs can regulate axon caliber size during development independently of myelin gene 
expression (Sanchez et al., 1996). 
 
CNS Myelination 
CNS myelination is a very precise process in which axons are ensheathed by myelin membrane 
produced by OLGs.  Myelination occurs in a rostral to caudal direction in the spinal cord and in a 
caudal to rostral direction in the brain.  In the cerebral hemispheres of rodent brain, myelination 
begins around postnatal day 12, with its most active period of myelination between days 15 and 
40 (Fig. 1-1C) (Kanfer et al., 1989).  In humans, myelination begins in the fetus, but reaches its 
peak in the brain during the first postnatal year (Baumann and Pham-Dinh, 2001).  Myelination 
continues into the third decade of life in some areas of the human brain (Figure 1-1B) (Yakovlev 
and Lecours, 1966).  This ability to myelinate late into life, which is not present in other species 
including rodents and chimpanzees, suggests myelin may play a significant role in optimizing 
information processing by experience (Figure 1-1B) (Miller et al., 2012; Fields 2008).  
Myelination is typically studied in rodents due to their availability.  In addition to the differences 
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in timing of myelination mentioned previously, there are several other main differences between 
rodents and humans that should be taken into consideration when extrapolating myelin studies 
from rodents to humans.  First, some brain regions that can be myelinated in the human, such 
as neocortical regions, are lacking in mice brain.  While others, such as the olfactory bulb, are 
overdeveloped in mice compared to humans.  Additional sources of OLG progenitor cells 
(OPCs) in the brain may also be present in the human brain.  As will be discussed further, 
humans and rodents express different isoforms of myelin basic protein (MBP) during adulthood. 
Finally, OLG lineage cells from humans and rodents have been shown to respond differently to 
certain factors (Bradl and Lassmann, 2010; Jakovcevski et al., 2009).  In chapter 2, myelin 
changes present in fragile X syndrome (FXS) were found not to be mimicked in the mouse 
model.  When evaluating these results it is important to be mindful of the differences in 
myelination between humans and mice.   
Myelination is tightly regulated, both temporally and spatially.  For instance, social deprivation 
during a critical period of development in the mouse leads to hypomyelination in the prefrontal 
cortex.  Return of the mice to a social environment after that critical time does not restore 
myelination (Makinodan et al., 2012).  In addition, the age of human fetuses can be accurately 
deduced based on which pathways are myelinated (Baumann and Pham- Dinh, 2001).  
OLG differentiation occurs in distinct stages and begins with OPCs, which in the rodent cerebral 
hemispheres originate in the subventricular zone (SVZ).   OPCs are bipolar, migratory, and 
proliferative.  As they migrate from the SVZ, clusters of OPCs line along axonal tracts that will 
become myelinated.  There is evidence that this alignment may be mediated by astrocytes in 
vivo (Meyer-Franke et al., 1999).  Some of the OLG progenitors in the cluster will eventually 
adhere to axons and differentiate into myelinating OLGs.  Axon signaling to the OLG is thought 
to regulate OLG differentiation leading to myelination of that axon.  This process is discussed in 
the section below.  
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OLG differentiation occurs in stages which can be identified by the expression of specific 
proteins (Fig. 1-2).  As previously stated, OLGs begin as OPCs.  They then transform into pre-
oligodendrocytes, which are still proliferative but much less mobile.  In vivo, this transformation 
occurs to cells lined up along future white matter tracts.  Upon proper signaling the pre-
oligodendrocyte can become an immature OLG, with increased processes and the expression 
of the first myelin specific protein, 3’, 5’-cyclic-nucleotide phosphohydrolase (CNP).  These cells 
eventually will possess MBP mRNA but not express MBP (Zeller et al., 1985).  One to two days 
after the first appearance of MBP mRNA, MBP, myelin-associated glycoprotein (MAG), and 
proteolipid protein (PLP) can be detected and the OLG will be considered a non-myelinating 
mature OLG.  When OLGs form compact myelin sheaths along axons they are then mature, 
myelinating OLGs; these cells now express the myelin oligodendrocytic glycoprotein (MOG) 
(Baumann and Pham-Dinh, 2001).  Differentiation of OLGs in culture mimics that of in vivo, 
even without the presence of neurons (Temple and Raff, 1986). 
Electrical activity of neurons strongly affects myelination, both during the onset of myelination 
and throughout life.  It appears to regulate whether or not an axon becomes myelinated, it may 
also regulate the extent of myelination on the axon.  OPC proliferation in the rat optic nerve is 
dependent on neuronal activity, as is myelination (Demerens et al., 1996; Barres and Raff, 
1993).  Mice maintained without light since birth have a reduced number of myelinated axons in 
the optic nerve, and premature opening of eyes in neonatal rabbits causes premature 
myelination (Tauber et al., 1980; Gyllensten and Malmfors, 1963).  In vitro, the induction of 
neuronal activity promotes OLG survival, differentiation, and axonal myelination (Gary et al., 
2012; Ishibashi et al., 2006; Stevens et al., 2002).  Activity is thought to trigger myelination in 
the human brain as well.  Magnetic resonance imaging (MRI) of humans has revealed that early 
experience in newborns leads to increased myelination (Als et al., 2004).  On the other hand, a 
reduction in corpus callosum area is present in children who are victims of neglect (Teicher et 
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al., 2004).  Comparison of brain tracts associated with musical performance in pianists and non-
musicians showed that playing the piano accompanies an increase in myelination of those tracts 
and the number of hours practiced in childhood correlates with the extent of the myelin increase 
(Bengtsson et al., 2005). 
 
Signals regulating myelin synthesis 
Extracellular signaling to OLGs 
 
In vitro, OLGs can differentiate and express MBP and other myelin proteins in the absence of 
axons.  However, in vivo OLG differentiation and myelination is believed to be regulated by 
external signals, including the axon.  Studies indicate that in the CNS the size of an axon may 
determine whether or not it is myelinated, which may be independent of any specific signaling 
from the neuron (Lee et al., 2012;  Rosenberg et al., 2008).  Experiments performed in zebrafish 
CNS stress the impact axons have on myelination.  Zebrafish CNS has two very large axons, 
called the Mauthner axons, which are myelinated first.  When genetically mutated zebrafish with 
an increased number of Mauthner axons were examined, the extra Mauthner axons were found 
to be myelinated properly and myelination was not accompanied by an increase in OLG 
number.  Already existing OLGs were producing more myelin sheaths than normal, which 
shows the ability of axons to influence the myelinating potential of an OLG (Almeida et al., 
2011).   It is not known if Mauthner axons express signals which promote myelination, but 
signaling molecules have been identified on other axons that lead to myelination.  One such 
protein is neuregulin-1.  It communicates with OLGs by binding to ErbB receptors on OLGs.  
Hypomyelination occurs in mice with disruption in neuregulin-1-ErbB signaling and 
overexpression of neuregulin-1 can cause small caliber axons not typically myelinated to 
become myelinated (Makinodan et al., 2012; Brinkman 2008).  Neuregulin-1 expression is 
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regulated by neuronal activity and myelination in vitro occurs preferentially on electrically active 
axons (Liu et al., 2011; Wake et al., 2011).   Additional signaling molecules expressed on the 
cell surface have been shown to participate in communication between axons and OLGs and 
regulate myelination.  These include the expression of polysialylated-neural cell adhesion 
molecule (PSA-NCAM) and Jagged1 on neurons and Notch1 and LINGO-1 on OLGs (Mi et al., 
2005; Charles et al., 2000; Wang et al., 1998).   
Several other signals influence the onset of myelination.  For instance, the astrocytic tissue 
inhibitor of metalloproteinase-1 (TIMP-1) promotes the differentiation of OLGs and leukemia 
inhibitory factor (LIF) produced by astrocytes in response to neuron electrical activity promotes 
myelination in co-cultures (Moore et al., 2011; Ishibashi et al., 2006).   In addition, extracellular 
matrix proteins, such as laminins, and growth factors secreted by neurons and astrocytes, such 
as fibroblast growth factors, also can influence differentiation (Relucio et al., 2009; Bansal 
2002).   
Intracellular Signaling to OLGs: 
Intracellular pathways that incorporate the external signals that lead to myelination are present 
in OLGs.  One intracellular signaling molecule that has been examined is Fyn kinase.  Fyn is 
activated by phosphorylation and dephosphorylation events at different sites on the molecule 
(Laursen et al., 2009).  There are numerous regulators of Fyn function, with glutamate released 
from electrically active axons as a potential additional regulator (Ahrendsen and Macklin, 2013; 
Wake et al., 2011).   Mice deficient in Fyn do not develop myelin properly and have defects in 
MBP transcription and translation.  The mitogen-activated protein kinase (MAPK)/extracellular 
related kinase (ERK) pathway along with the PI3 kinase/Akt/mTOR pathway in OLGs have also 
been proven to play a major role in myelination (Ahrendsen and Macklin, 2013). 
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Figure 1-1:  Timing of myelination in humans and rodents.  (A)  Timing of onset of 
myelination in different areas of human CNS (adapted from Yakovlev and Lecours, 1966).  (B)  
Timing at which myelination terminates in different areas of the human CNS (adapted from 
Yakovlev and Lecours, 1966).  (C)  MBP accumulation, which correlates with myelination timing, 
in the rodent cerebral hemispheres (adapted from Delassalle et al., 1981).   
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Figure 1-2: Developmental stages of OLG lineage cells.  Myelin specific proteins that can be 
detected at each stage of development are listed.  The pattern of OLG development is similar in 
vitro and in vivo.  
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Myelin and human disease 
The importance of proper myelin function is evident in disorders of myelin. Myelin disorders in 
humans can lead to sensory-motor problems, paralysis, cognitive impairment, mental 
retardation, seizures, and death (Fields, 2008).  They can be caused by the failure to form 
myelin, termed dysmyelination, or by demyelination, which is the breakdown of myelin.  As 
expected, genetic mutations that directly affect OLGs result in myelin disorders.  Such diseases 
include Canavan’s Disease, 18q-syndrome, and Pelizaeus-Merzbacher Disease (Kumar et al., 
2006; Mimault et al., 1999; Kolodny, 1993).  White matter disorders can be caused by other 
factors in which OLG dysfunction is not primary.  In Niemann–Pick Type C, neurons are 
dysfunctional due to impairment in internal cholesterol transport.  Faulty signaling from the axon 
to the OLG is thought to be a cause of the myelin phenotype in that disorder (Takikita et al., 
2004).  Alexander’s disease results in myelin abnormalities due to astrocytic impairment caused 
by a mutation in glial fibrillary acidic protein (GFAP) (Mignot et al., 2004).  Breakdown of the 
blood brain barrier through inflammation or hypertension can also be responsible for myelin 
problems (van Dijk et al., 2004).  Multiple sclerosis may be the most common known of all 
myelin disorders.  It presents with demyelination in the CNS and is believed to be an 
autoimmune disorder.  Neurological symptoms in multiple sclerosis usually correspond with the 
demyelinated region, such as optic nerve myelin lesions leading to vision loss or spinal cord 
lesions leading to bladder dysfunction (Keegan and Noseworthy, 2002).   
Myelin and Cognition 
Neuronal activity is a strong regulator of myelination and experiences which trigger neuronal 
activity help shape the myelin makeup of our brains.  Thus, myelin is assumed to be important 
for learning and cognition.  Recent evidence supports this assumption.  For instance, MRI has 
revealed differences in myelin in individuals with autism, and a correlation between cognitive 
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processing speeds and myelin integrity was found in elderly individuals (Lu et al., 2013; Hoeft et 
al., 2010).  In addition, polymorphisms in myelin genes and reduced levels of transcripts 
involved in OLG differentiation and survival have been linked to depression, schizophrenia, and 
other disorders (Fields, 2008).  The proposed mechanism through which myelin influences 
cognition is by changing the conduction velocity of impulses through axons.  A main idea in 
synaptic plasticity is that synaptic inputs that arrive together in the post-synaptic neuron are 
retained and strengthened, while non-coincident inputs are eliminated.  Altering of the 
conduction velocity by changes in myelin could lead to differences in the timing at which inputs 
arrive together and therefore alter connectivity in the brain (Fields 2008; Nave 2010).    
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Myelin Basic Protein (MBP) 
MBP is one of the two major proteins that make up myelin in the CNS, along with PLP.  MBP is 
a myelin specific protein which constitutes about 30% of the total protein in CNS myelin and is 
expressed at much lower levels in the PNS (Baumann and Pham-Dinh 2001; Boggs, 2006a).  
MBP plays a more prominent role in the CNS than in the PNS.  In the CNS, MBP is synthesized 
only by OLGs and its expression follows the timing of myelination, as described in the previous 
section (Fig. 1-1C).  MBP mRNA appearance precedes that of MBP.  At the very early stage of 
myelination MBP mRNA is restricted to the OLG cell body.  However, as myelination proceeds 
MBP mRNA is present throughout the OLG processes (Verity and Campognoni, 1988).  
 
MBP is transcribed from the GOLLI (Genes of Oligodendrocyte Lineage) gene complex that 
contains 10 exons in humans and 11 exons in mice, seven of which give rise to MBP (Givogri et 
al., 2001; Pribyl et al., 1993).  The exons giving rise to MBP are highly conserved between mice 
and humans (Pribyl et al., 1993).  Due to alternative splicing, different isoforms of MBP are 
present both in rodents and humans (Fig. 1-3).  All MBP transcripts have exon 7, which contains 
the 3’ untranslated region (UTR) that is crucial for proper MBP mRNA translation.  Several 
experiments reported in the following chapters were performed using mRNA for the 14 kDa 
isoform of rat MBP mRNA.  The 3’ UTR of this mRNA is present in all isoforms.  The expression 
of MBP isoforms changes during development, as the exon II containing isoforms are more 
highly expressed prior to the onset of myelination and the forms lacking exon II are more highly 
expressed after (Barbarese et al., 1978).  In the rodent, the 14 kDa and 18.5 kDa isoforms are 
the isoforms predominantly expressed in adults while in humans the 18.5 kDa is most common 
(Quarles et al., 2006; Baumann and Pham-Dinh, 2001; Kamholz et al., 1986; Campagnoni and 
Macklin, 1988).  All isoforms are present in compact myelin, though isoforms lacking exon II can 
also locate to the nucleus (de Vries et al., 1997; Pedraza, 1997).  However, exon II is neither 
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required nor deleterious to compact myelin formation as transfection of exon II-negative MBP 
(14 kDa) or exon II-positive MBP (17.2 kDa) leads to similar restoration of myelination in a 
mouse model lacking MBP, the shiverer mouse (Kimura et al., 1998).  The myelin level was 
lower in the transgenic mouse than in the heterozygote shiverer mouse, despite similar amounts 
of MBP mRNA, suggesting all MBP isoforms are important for proper myelin formation.  
 
Analysis of rat brain has shown MBP to decay with rates of two different components.  MBP that 
decays at the fast component rate has a half-life of approximately 3 weeks, while MBP decaying 
at the rate of the slow component is stable (Sabri et al.,1974).  Measurements of MBP mRNA 
stability in P30 rodent brain slices showed no decay in MBP mRNA over 12 hours, indicating 
that its half-life is greater than 12 hours (Mathisen et al., 1997).   
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Figure 1-3:  MBP isoforms created by alternative splicing.  (A)  Rodent Golli gene with the 
original exon numbering of MBP above and that for the Golli gene below (adapted from Quarles 
et al., 2006).  (B)  Alternate splice variants of MBP in murine and humans (adapted from Boggs, 
2006a).  
 
 
Functions of MBP 
MBP’s main function in CNS myelin is the formation of compact myelin.  The shiverer mouse, in 
which MBP is not expressed due to a large deletion in the MBP gene, lacks compact CNS 
myelin (Readhead and Hood, 1990).   The Long Evans shaker rat, which has undetectable 
levels of MBP due to a mutation in the MBP gene, also does not form compact CNS myelin 
(O’Connor et al., 1999).   In the formation of compact myelin, the external faces of the plasma 
membrane appose each other to form the double intraperiod line.  That is followed by the 
apposition of the cytoplasmic sides of the membrane to form the major dense line and then the 
cytosol is extruded (Baumann and Pham-Dinh, 2001).  MBP, which is positively charged, is 
located on the cytoplasmic side of the membrane (Fig. 1-4).  It is thought MBP may compact the 
membrane by coupling the cytoplasmic sides through its binding to the negative membrane 
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lipids (Harauz et al, 2004; Campagnoni and Skoff, 2001).  Crosses of different mouse models 
with the disruption of the MBP gene were made to create mice with differing levels of MBP 
transcript and MBP.  When MBP levels were below 50% of control, the thickness of the myelin 
sheath and the number of myelinated axons paralleled the level of MBP.  At protein levels 
between 50% and 100% of control, the thickness of the myelin sheath and number of 
myelinated axons remained constant.  This suggests that MBP levels 50% of normal are 
sufficient for proper myelin thickness and for the proper quantity of axons to be myelinated 
(Shine et al., 1992).  Despite the normal appearance of myelin, MBP levels of 50% of control 
slightly alter myelin function (Martin et al., 2006). 
 
MBP potentially plays many other roles besides compaction of the myelin membrane.  MBP has 
been suggested to be involved in the neuronal dependent clustering of galactosylceramide 
(GalC) in plasma membranes of OLGs (Fitzner et al., 2006).  Wild type OLGs when co-cultured 
with neurons display a clustering of GalC in the plasma membrane that is not observed in OLGs 
of shiverer mice, which lack MBP (Fitzner et al., 2006).  PLP expression is also affected by 
MBP, as levels of PLP mRNA in the shiverer mouse are reduced to less than 55% of controls 
(Sorg et al., 1987).  In addition, MBP colocalizes with voltage gated calcium channels in OLGs 
and may be involved in regulating calcium influx into OLGs (Smith et al., 2011).  MBP is also 
capable of interacting with the cytoskeleton of OLGs.  Actin can be bound by MBP in vitro and 
MBP has at least two actin binding sites (Hill and Harauz, 2005; Roth et al., 1993).  MBP can 
also bind tubulin and cause bundling of microtubules and tubulin polymerization (Hill and 
Harauz, 2005; Modesti and Barra, 1986).  Shiverer mice do not display colocalization of 
microtubular structures and actin filaments as found in wild type and they also display 
microtubules with a distorted sizes and smaller processes (Dyer et al., 1995).  MBP is also 
involved in signaling in the OLG.  For instance, cultured shiverer OLGs do not differentiate as 
well in the presence of growth factors as wild type (Seiwa et al., 2002).  Treating cultured wild 
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type OLGs with GalC antibody resulted in decreased MBP phosphorylation and loss of 
microtubule structure, neither of which are found when treating shiverer OLGs (Dyer et al., 
1994).  Finally, MBP has been shown to partially colocalize with actin at the edge of OLG 
membrane sheaths, suggesting MBP may act as messenger between the two (Boggs et al., 
2006b).   
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Figure 1-4:  MBP and compact myelin.  (A)  Myelinated axon in the mouse optic nerve (image 
provided by Dr. Elisa Barbarese).  (B)  High magnification of compact myelin sheath shown in A. 
Darker lines are major dense lines.  Major dense lines are formed by the compaction of the 
cytoplasmic side of the myelin membrane, where MBP is present.  MBP is necessary for 
compact myelin in the CNS.  (C)  Cartoon depicting MBP and PLP in the CNS myelin 
membrane.  The extracellular face of the membrane is called the intraperiod line.  There are two 
intraperiod lines between each two major dense lines.   
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Mutations in the MBP gene 
18q-syndrome 
There is no known human disorder in which MBP is absent.  However, some patients with 18q-
syndrome have only one copy of the MBP gene.  18q-syndrome is caused by the deletion of 
part of the long arm of chromosome 18, which comprises the MBP gene.  Gay et al. (1997) 
examined white matter of a18q-syndrome patient with both copies of the MBP gene and that of 
patients with only one copy of the gene.  Interestingly, they found that the patient with both 
copies of the gene did not exhibit the incomplete myelination that was present in those 
individuals with one copy of the gene (Gay et al., 1997).  This suggests that reductions in MBP 
expression in humans can lead to myelin abnormalities.  Whether or not those abnormalities 
relate to behavioral changes could not be ascertained from this study as patients displayed 
similar behaviors, such as mental retardation, regardless of the MBP gene copy number.   
Mouse Models involving MBP mutations  
The shiverer mouse is a result of a deletion in the MBP gene that leads to virtually no 
expression of MBP.  The shiverer mouse presents with intention tremor starting around P11, is 
subject to seizures, displays learning deficits, and dies around five months of age (Readhead 
and Hood, 1990; Inagawa et al., 1988).  Shiverer mice display hypomyelination and the absence 
of compact myelin.  Their axons are smaller and changes to the organization of the axonal 
cytoskeleton are present (Brady et al., 1999).  However, there is no axonal degradation (Griffiths 
et al., 1998). Though MBP is expressed in both the PNS and CNS, the absence of MBP from 
the PNS does not lead to noticeable myelin changes (Kirschner and Ganser, 1980).  Mice that 
are heterozygous for the shiverer mutation (+/shi) have half the amount of MBP protein, but 
their myelin appears normal. They do not have obvious motor/locomotion abnormalities despite 
a slight decrease in conduction velocity (Martin et al., 2006; Shine et al. 1992).    
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MBP mRNA transport and translation 
 
MBP mRNA and hnRNP A2 containing granules 
 
In mature OLGs, subcellular fractionation and in situ hybridization has revealed that MBP mRNA 
is found in the myelin compartment of OLG processes where expression of MBP is much 
greater than in the perikaryon (Trapp et al., 1987; Colman et al., 1982).  Microinjection of MBP 
mRNA has shown that MBP mRNA is localized to the myelin compartment via a multi-step 
pathway.  That pathway begins with RNA assembling into granules in the perikaryon.  Granules 
are then transported along microtubules of the processes until they are properly localized in the 
myelin compartment (Ainger et al., 1993).  Granules are non-membranous complexes with a 
radius of approximately 0.7 µm (Barbarese et al., 1995).  In situ hybridization and 
immunofluorescence of cultured OLGs has revealed that MBP mRNA containing granules 
contain, among others, the molecular motors kinesin and dynein and the machinery necessary 
for protein synthesis, such as ribosomes, aminoacyl t-RNA synthetases, and the elongation 
factor EF1 (Carson et al., 2001; Barbarese  et al., 1995). Despite the presence of translational 
machinery, evidence suggests that the translation of RNAs in granules is suppressed until the 
RNAs reach their final destination (Kosturko et al., 2006).  Granules travel to their destinations 
in a microtubule-dependent process, as transport of microinjected MBP mRNA was inhibited in 
OLGs treated with taxol to stabilize microtubules or nocodazole to disrupt microtubules.  
Transport does not necessitate microfilaments, as disruption with cytochalisin B had no effect 
on the translocation of MBP mRNA (Carson et al., 1997).  
RNAs assemble into specific granules depending on their intended final destination.  For 
instance, granules containing RNA for soluble proteins, such as globin, stay in the perikaryon.  
PLP mRNA or RNA of other membrane proteins are found in granules destined for the 
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endoplasmic reticulum (Carson et al., 2001).  The type of granule a RNA incorporates into 
depends on the cis-acting elements in the RNA and the trans-acting elements in the cell 
(Carson et al., 2001).   MBP mRNA contains two tandemly duplicated cis- acting sequences 
termed the A2 Response Element (A2RE) in its 3’ UTR (Fig. 1-5).  Heterogeneous nuclear 
ribonucleoprotein A2 (hnRNP A2) binds to the A2RE and allows MBP mRNA to assemble into 
hnRNP A2 containing granules (Munro et al., 1999; Ainger et al., 1997; Hoek et al., 1998 ).  
HnRNP A2 containing granules have been estimated to contain around 30 molecules of RNA 
(Mouland et al., 2001).  The MBP mRNA A2RE in humans is homologous to that of rodents and 
the sequence of hnRNP A2 is highly conserved in human, rat, and frog (Ainger et al., 1997; 
Brumwell et al., 2002).   
HnRNP A2 has four different isoforms (A2, A2b, B1, and B1b).  The A2b isoform is the 
predominant cytoplasmic isoform in OLGs and neuronal cells and is the major isoform 
responsible for the transport of A2RE containing mRNAs (Han et al., 2010).  HnRNP A2 can 
dimerize through its glycine-rich dimerization domain and contains a nuclear localization domain 
and two RNA binding domains (RBD1 and RBD2), with the RBD2 domain necessary for proper 
targeting of hnRNP A2 to the OLG periphery (Brumwell et al., 2002).  The specific binding of 
hnRNP A2 to the A2RE is formed by the tandem RBDs and its proximal C terminal region.  
HnRNP A2 is also capable of binding more weakly and non-specifically to RNA through a region 
different than A2RE (Shan et al., 2000).  In neurons, hnRNP A2 colocalizes in granules with 
A2RE containing RNAs 75% of the time and non-A2RE containing RNAs 25% of the time (Gao 
et al., 2008).   HnRNP A2 is present in the nucleus, the perikaryon, and in the periphery of 
OLGs, though its expression in the nucleus is over 20 times greater than in the cytoplasm 
(Brumwell et al., 2002). 
Several studies have emphasized the importance of MBP mRNA binding to hnRNP A2 through 
the A2RE for proper localization of MBP mRNA to OLG processes.  First, microinjection of MBP 
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mRNA with and without the A2RE demonstrated the necessity of the A2RE for localization of 
MBP mRNA (Ainger et al., 1997).  Second, the addition of the A2RE sequence to the 3’ UTR of 
green fluorescent protein (GFP) RNA led to a significant increase in GFP RNA traveling to OLG 
processes (Ainger et al., 1997). Third, mutations in the A2RE which hinder A2 binding caused 
decreased localization of A2RE-GFP RNA to OLG processes, and OLGs treated with hnRNP 
A2 siRNA showed MBP mRNA confined to the cell body (Laursen et al., 2011; Munro et al., 
1999).  
There are several other proteins in the brain whose RNAs are known to contain A2RE 
sequences.  In OLGs, one of several transcripts for myelin-associated oligodendrocytic basic 
protein (MOBP) contains an A2RE-like sequence and localizes to the myelin compartment 
(Carson et al., 2001).   RNAs transported to dendrites in neurons, such as activity-regulated 
cytoskeleton-associated protein (Arc) and α-cam kinase II, also have A2RE sequences. Their 
proper localization has been shown to be dependent on their A2RE and binding of hnRNP A2 
(Gao et al., 2008).   
Regulation of MBP mRNA translation through the 3’UTR  
In addition to the binding of hnRNP A2, the 3’ UTR of MBP mRNA can regulate MBP translation 
in several other ways.  First, the 3’UTR of MBP mRNA contains a polyadenylation sequence 
AAUAA and cytoplasmic polyadenylation element (CPE), which are thought to be necessary for 
cytoplasmic polyadenylation (Fig. 1-5) (Mendez et al., 2000). The cleavage and polyadenylation 
specificity factor (CPSF) protein binds the AAUAA and is responsible for recruitment of poly(A) 
polymerase (Dickson et al., 1999).  The cytoplasmic polyadenylation element binding protein 
(CPEB) binds to the CPE and phosphorylation of the CPEB leads to polyadenylation and 
translation of RNA in oocytes (Mendez et al., 2000).  Examination of neurons suggests that 
cytoplasmic polyadenylation through CPEB phosphorylation occurs similarly in neuronal RNAs 
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with a CPE sequence (Du and Richter, 2005).  Though further work is needed to asses this 
possibility in OLGs, regulation of cytoplasmic polyadenylation of the MBP transcript through 
sequences in its 3’ UTR may act in concert with other elements to modulate MBP translation.   
The 3’UTR contains several repeats of an hnRNP-K sequence that binds hnRNP K (Laursen et 
al., 2011).  Knockdown of hnRNP-K in cultured OLGs results in reduced MBP mRNA expression 
while MAG expression is unchanged, suggesting hnRNP-K specifically inhibits the translation of 
MBP mRNA (Laursen et al., 2011).  It has also been reported that a small non-coding RNA 715 
(sncRNA 715) binds to MBP mRNA 3’ UTR and inhibits its translation (Figure 1-5).  Increases in 
the levels of sncRNA 715 have been detected in multiple sclerosis patients (Bauer et al., 2012).  
The fragile X mental retardation protein (FMRP)  binds to the 3’ UTR of MBP mRNA  and  has 
also been suggested to inhibit MBP mRNA translation in vivo (Fig. 1-5)(Darnell et al., 2011; Li et 
al., 2001; Wang et al., 2004).   
Ribonucleoproteins that bind hnRNP A2 have also been implicated in regulating the translation 
of MBP mRNA.  HnRNP F associates with MBP mRNA through binding to hnRNP A2, though it 
has been suggested it may bind directly to MBP mRNA (White et al., 2012).  Knockdown of 
hnRNP F leads to decreased MBP expression in primary OLG cultures.  Knockdown or 
overexpression of hnRNP F in an OLG cell line caused increased amounts of MBP mRNA in the 
processes and decreased amounts of MBP translation (White et al., 2012).  HnRNP F is 
phosphorylated by Fyn kinase, which is the proposed mechanism to lift the inhibition of MBP 
mRNA translation by HnRNP F.   HnRNP E1 also binds to hnRNP A2 and inhibits the translation 
of MBP mRNA.  The two ribonucleoproteins bind to each other in vitro and hnRNP E1 
colocalizes with A2RE-RNA and hnRNP A2 in OLGs.  Translation of GFP RNA containing an 
A2RE is inhibited by hnRNPE1 overexpression in B104 cells (a rat neuroblastoma cell line), 
while inhibition of translation of GFP RNA without an A2RE does not occur when hnRNPE1 is 
overexpressed (Kosturko et al., 2006).    
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Figure 1-5:  MBP mRNA and its 3’ UTR.  The 3’ UTR of MBP contains a CPE sequence, two 
tandemly located A2RE sequences, several hnRNP K binding sequences, and a 
polyadenylation sequence.  FMRP also binds the 3’UTR of MBP mRNA, though where FMRP 
binds in the 3’ UTR is unknown.  
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Fragile X Syndrome (FXS) and fragile X-associated tremor/ataxia syndrome (FXTAS): 
Trinucleotide Repeat Disorders 
Trinucleotide repeat disorders are neurological disorders that are caused by the expansion of 
trinucleotide repeats in some genes.  The presence of the expansion can lead to gene silencing, 
mRNA toxicity by the altered transcript, or toxicity from the protein encoded by the gene (Li and 
Bonini, 2010; Orr and Zoghbi, 2007).  FXS and FXTAS are trinucleotide repeat disorders due to 
the expansion of CGG repeats in the 5’ untranslated region (UTR) of the FMR1 gene, which 
encodes the fragile X mental retardation protein (FMRP).  The FMR1 gene usually contains 
between 5 and 55 CGG repeats (Cornish et al., 2009).  FXS is caused by the expansion of 
repeats to more than 200.  Individuals in which the expansion in the FMR1 gene leads to CGG 
repeats numbering between 55 and 200 are considered to have the fragile X premutation.  
Many of these individuals, greater than 50% of males age 70 or older, will develop symptoms of 
FXTAS (Oostra and Willemsen, 2009).   
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CGG repeats in 5’ 
UTR of FMR1 gene 
FMR1 mRNA levels FMRP Protein level Phenotype 
< 55 normal normal normal 
55-200 increased normal or slightly 
reduced 
FXTAS 
>200 significantly reduced 
to not present 
significantly reduced 
to not present 
Fragile X Syndrome 
 
Table 1-1:  The effects of CGG repeat expansion in the 5’ UTR of the FMR1 gene.  
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FMRP and Fragile X Syndrome 
 
FXS is present in approximately 1 in 5000 males and 1 in 10,000 females worldwide (Coffee et 
al., 2009).  Transcription of the FMR1 gene, which is located to the X chromosome, does not 
occur or is significantly decreased in FXS because the presence of 200 or more CGG repeats in 
its 5’ UTR leads to hypermethylation of the repeats and the upstream CpG island in the 
promoter region (Pieretti et al., 1999).  Individuals with FXS display behavioral and cognitive 
abnormalities along with abnormalities in physical features, such as macroorchidism 
(Lachiewicz and Dawson, 1994).  Mental retardation and deficits in short term memory, visuo-
spatial processing, arithmetic, and executive functions are all associated with FXS (Schapiro et 
al., 1995).  Behavioral abnormalities include anxiety, social-interaction deficits, and hyperactivity 
(Tsiouris and Brown, 2004).  In addition, around 30% of males are diagnosed with full autism, 
and many more are diagnosed with an autism spectrum disorder (Harris et al., 2008).   
Differences in white matter in both adult and toddlers with FXS have been found using diffusion 
tensor imaging and MRI.  These differences include increases and decreases in white matter 
along with an increased number of myelinated nerve fibers (Hallahan et al., 2011; Hoeft et al., 
2011; Barnea-Garoly et al., 2003).  Many of these differences correlate with regions or 
pathways in the brain that are involved in behavior or cognition that are deficient in FXS 
patients.  For instance, it is believed that one function of the ventral frontostriatal pathway is 
cognitive inhibition.  Deficits in cognitive inhibition are found in many FXS patients, and more 
myelinated fibers in that pathway have been reported in toddlers with FXS (Haas et al., 2009).    
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FMRP: a translational inhibitor 
Twelve alternatively spliced isoforms of FMRP have been identified in the rodent brain (Brackett 
et al., 2013).  Limited studies have been performed on the functions of the different isoforms 
and most work focuses on the main isoform of FMRP, a 632 amino acid protein that contains 
three common RNA-binding domains, a nuclear localization signal (NLS) and a nuclear export 
signal (NES) (Fig. 1-6) (Bhakar et al., 2012).  FMRP expression is highest in the brain and 
testes, with neurons being the highest expressing cell type in the brain (Devys et al., 1993; 
Hinds et al., 1993).  FMRP binds to 4% of mRNA in the human brain and is found mostly in the 
cytoplasm, though a small percentage of FMRP may be present in the nucleus (Feng et al., 
1997; Ashley et al., 1993).  The role of FMRP in the nucleus has not been extensively studied, 
but it is important as individuals with a missense mutation in the NLS have developmental delay 
(Collins et al, 2010).   
The role of FMRP in the cytoplasm has been examined in greater detail.  FMRP is present in 
mRNA containing granules in the cytoplasm and it has been demonstrated that FMRP 
represses the translation of several mRNAs in vivo.  Transcripts for Arc and αCam Kinase II 
contain A2RE sequences and are two of which that can be repressed (Zalfa et al., 2003).  The 
majority of the studies examining FMRP’s function have focused on neurons, in particular their 
dendritic spines.  In neurons, FMRP’s function has been shown to be mediated by signaling 
through NMDA receptors, muscarinic acetylcholine receptor, and group 1 metabotropic 
glutamate receptors (mGluR) (Lee et al., 2011; Volk et al., 2007; Bear et al., 2004).  Many of the 
phenotypes present in the Fmr1 KO mouse can be attenuated by group 1 mGluR inhibition and 
the “mGluR theory of fragile X” is very prominent in the field.  The “mGluR theory of fragile X” 
states that increased translation of proteins downstream of the mGluR signaling at synapses 
lead to the neurological and psychiatric dysfunction found in FXS (Bear et al., 2004) 
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The stage of translation that is affected by FMRP is undetermined, but there is evidence FMRP 
may inhibit at both the initiation and elongation stage.  The evidence that FMRP may exhibit 
translational repression at the initiation phase began with in vitro translation assays performed 
by Laggerbauer et al. (2001).  The assays showed that the presence of FMRP significantly 
decreased the amount of RNA that associated with 80s ribosomes. Further data supporting 
FMRP playing an inhibitory role during translation initiation was found in cleavage-stage 
Drosophila embryos.  In these embryos, FMRP associates with mRNPs but not polyribosomes 
(Monzo et al., 2006).    FMRP’s capability to recruit and/or stabilize CYFIP1 on the 5’ end of 
specific mRNA has been suggested as a mechanism to repress translation initiation.  CYFIP1 
inhibits translation by binding to eIF4e associated with the mRNA.  This prevents eIF4e from 
binding to eIF4g, which is needed for the initiation of cap dependent translation (Napoli et al., 
2008).  However, this inhibition may only occur in a subset of RNAs that FMRP binds to.  For 
instance, FMRP is known to bind its own RNA, yet that RNA was not found to be in any CYFIP1 
containing mRNPs (Napoli et al., 2008).    
FMRP has been found in multiple studies to be associated with polyribosomes, which provides 
evidence that FMRP may stall translation at the elongation step (Darnell et al., 2011; Stefani et 
al., 2004; Ceman et al., 2003; Weiler et al., 1997).  Rare cases of FXS are found in individuals 
with a point mutation in the KH domain of FMRP, I304N.  These individuals express normal 
amounts of FMRP, but the mutation inhibits the ability of FMRP to bind to polyribosomes (Feng 
et al., 1997b).    FMRP’s inhibition of translation on polyribosomes is mediated by its 
phosphorylation.  Phosphorylated FMRP associates with stalled polyribosomes and 
unphosphorylated FMRP is found on those that are actively translating (Ceman et al., 2003). 
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Figure 1-6:  FMRP protein and its functional domains.  The two K-homology domains (KH1 
and KH2) and the arginine-glycine-glycine (RGG) box are RNA binding domains.  Mutation in 
the NLS, R138Q, results in developmental delay in humans.  Mutation in the KH2 domain, 
I304N, abolishes FMRPs ability to associate with polyribosomes and results in FXS, despite 
normal quantities of FMRP.  S500 is a major phosphorylation site (adapted from Bhakar et al., 
2012). 
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FMRP, Oligodendrocytes, and MBP translation 
As previously stated, the study of FMRP has mainly focused on neurons.  Recent studies on 
astrocytes have demonstrated they express FMRP early in development and can influence 
neuronal phenotypes (Pacey and Doering, 2007; Jacobs and Doering, 2010).  Studies on 
FMRP’s effect on OLGs and myelin have been very limited.  Though limited, there is evidence 
to suggest a role for FMRP in OLGs, specifically in regulating MBP mRNA translation.  As 
described previously, white matter differences have been found in FXS.  Since myelination can 
be influenced by many factors, including some of neuronal and astrocytic origin, it is possible 
that dysfunction of these cell types leads to myelin abnormalities.  However, OLGs are the 
myelinating cells in the CNS so it is logical that primary OLG dysfunction could also lead to 
these changes.   
There are several pieces of evidence that suggest primary dysfunction in cells of the OLG 
lineage may occur in FXS.  First, it is thought that FMRP is expressed in at least some cells of 
the OLG lineage because Fmr1 mRNA has been detected in the OLG rich corpus callosum of 
adult mice and FMRP has been reported in OPCs and MBP-negative immature OLGs (Pacey 
and Doering, 2007; Wang et al., 2004; Hinds et al., 1993).  Second, receptors that are involved 
in signaling that regulates FMRP function in neurons (muscarinic acetylcholine receptors, 
NMDA receptors, and mGluR receptors) are all expressed on cells of the OLG lineage (Cao and 
Yao, 2013; Cui et al., 2006; Luyt et al., 2006).  For instance, NMDA receptors on OLGs are 
involved in mediating the differentiation and migration of OLGs (Cao and Yao, 2013).  Finally, 
there is preliminary evidence that FMRP may inhibit MBP mRNA translation in OLGs.  
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Figure 1-7:  Mechanism by which premature 
MBP expression may lead to cognitive and 
behavioral abnormalities in FXS and Fmr1 KO 
mice. 
 
As discussed previously, MBP is critical 
for the formation of CNS compact 
myelin and constitutes 30% of all 
myelin proteins.  FMRP binds to MBP 
mRNA, both in vitro and in vivo, and 
can inhibit MBP translation in vitro 
(Darnell et al., 2011; Wang et al., 2004; 
Li et al., 2001).  The ability of FMRP to 
inhibit translation in vitro and to bind to 
MBP mRNA is dependent on the 3’UTR 
of MBP mRNA (Wang et al., 2004; Li et 
al., 2001).  The temporally coordinated 
appearance of MBP and  
disappearance of FMRP in OLGs 
further suggested that FMRP  inhibits 
MBP mRNA translation in OLGs.   
Wang et al. (2004) reported that in 
cultured rat OLGs, OLG cell lines, and 
OLGs of P2 mouse brain that FMRP was 
present only in OLGs not expressing MBP.  These findings have led to the interpretation that 
during development FMRP inhibits the translation of MBP mRNA in immature OLGs and that a 
reduction in FMRP allows for the translation of MBP mRNA in mature, MBP expressing OLGs 
(Wang et al., 2004).  If this is indeed true, the expression of MBP may occur prematurely in FXS 
due to the absence of the translational repression of FMRP.  This may lead to not only myelin 
differences in FXS but could also alter connectivity in the brain by changes in conduction 
velocity caused by the myelin changes (Fig. 1-7).    
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Fmr1 KO mouse model 
The FMR1 gene is highly conserved among species and rodent FMRP has a 97% amino acid 
sequence homology with the human protein and is structurally conserved (Ashley et al., 1993).  
The pattern of FMRP expression in tissues is also very similar in the human and mouse.  The 
Fmr1 KO mouse was created by inserting a neomycin cassette in exon 5.  These mice lack 
normal Fmr1 mRNA and FMRP protein.  The Fmr1 KO mouse is a commonly used model to 
study FXS and shares many characteristics with FXS patients, such as macroorchidism, 
hyperactivity, and learning deficits (Dutch-Belgian Fragile X Consortium, 1994).  The Fmr1 KO 
mice used for our studies are on a C57/B6 background, Fmr1 KO mice on different genetic 
backgrounds have different behavioral phenotypes (Spencer et al., 2011).  
Myelination and in particular MBP expression has not been extensively studied in the Fmr1 KO.  
Myelin in P30 Fmr1 KO mouse had been examined by Ellegood et al., (2010) by diffusion tensor 
imaging and MRI and no difference was found at that time point.  MBP and myelination in the 
cerebellum of Fmr1 KO was only very recently examined.  This study found decreased amounts 
of MBP and CNP in the cerebellum at day 7 and MBP reduction continued at day15, while CNP 
levels returned to normal.  MBP levels returned to normal at P30, but then became higher than 
normal in adulthood.  Electron microscopy at P7 revealed differences in the number of 
myelinated axons and g-ratio, but these were not present at P15.  A decrease in the number of 
progenitors was present at P7 revealing a possible reason for the myelin alterations in the 
cerebellum of the Fmr1 KO (Pacey et al., 2013).  Our work, presented in Chapter 2, is the only 
published examination of the expression of MBP and other myelin proteins in the cerebral 
hemispheres of the Fmr1 KO mouse over the course of development.  
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Fragile X premutation and FXTAS 
The fragile X premutation is present when the FMR1 gene contains between 55 and 200 CGG 
repeats, which are unmethylated (Cornish et al., 2009). Individuals with the fragile X pre-
mutation have increased levels of FMR1 mRNA and normal to slightly reduced levels of FMRP 
(Peprah et al., 2010; Tassone et al., 2000).  Of those, around 20% of women are diagnosed 
with premature ovarian insufficiency and one third of all pre-mutation carriers have symptoms of 
FXTAS by the age of 50 (Oostra and Willemsen, 2009).  The presence of FMR1 mRNA in 
intranuclear inclusions in FXTAS patients, increased levels of FMR1 mRNA, and slight or no 
change in the presence of FMRP has led to the belief that mRNA toxicity is the cause of the 
neurological deficits associated with FXTAS and the fragile X premutation.   
Those affected with FXTAS present with intention tremor and cerebellar gait ataxia that is 
frequently accompanied by autonomic dysfunction, Parkinsonism, and cognitive decline 
(Hagerman and Hagerman, 2004).  Purkinje cell loss and solitary ubiquitin-positive intranuclear 
inclusions in both neurons and astrocytes in post-mortem tissue are hallmarks of FXTAS. The 
number of inclusions correlates with the number of CGG repeats (Greco et al., 2006).  Mouse 
models of the fragile X premutation also include ubiquitin-positive intranuclear inclusions in 
neurons and astrocytes and display some cognitive and motor difficulties (Hunsaker et al., 2009; 
Van Dam et al., 2005).  FXTAS is generally perceived to be a disease with an onset late in life, 
however there is evidence that FXTAS may be the manifestation of a process that begins early 
in development.  For instance, cultured P1 neurons and embryonic fibroblasts from the fragile X 
premutation knock-in mouse display abnormalities (Garcia-Arocena and Hagerman, 2010).  
Also, behavior and cognitive difficulties and an increased susceptibility to seizures are present 
in youth with the fragile X premutation, demonstrating the premutation transcript may exert 
toxicity early in life (Aziz et al., 2003).   
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FXTAS and Myelin 
Symptoms of FXTAS, such as intention tremor, indicate myelin plays a strong role in the 
disorder.  Indeed, MRI and examination of post mortem tissue of FXTAS patients have shown 
the presence of cerebral and cerebellar white matter lesions, especially in the middle cerebellar 
peduncles, and significant astrocytic pathology in the cerebral white matter (Garcia-Arocena and 
Hagerman, 2010; Cohen et al., 2006; Greco et al., 2006).  Changes in myelin in the presence of 
the premutation may be occurring throughout life as asymptomatic premutation carriers around 
45 years of age show white matter reductions (Battistella et al., 2013).  These changes may be 
due to improper myelination during development, improper maintenance of myelin, and/or 
failure to properly remyelinate following demyelination.  There are no obvious intranuclear 
inclusions in OLGs, though isolation of intranuclear inclusions from a FXTAS patient contained 
MBP (Iwahashi et al., 2006).  The cause of these lesions in FXTAS may be due to dysfunction 
of the cell types that display intranuclear inclusions in FXTAS, which are neurons and 
astrocytes.  However, primary dysfunction in OLGs may also contribute. 
A mechanism by which primary OLG dysfunction may occur is through altered translation of 
MBP mRNA.  The presence of hnRNP A2 in intranuclear inclusions suggests that hnRNP A2 
may be able to bind to the fragile X premutation transcript through its CGG repeats (Iwahashi et 
al., 2006).  The binding of hnRNP A2 to the premutation transcript suggests several possibilities 
by which MBP expression can be altered, as MBP mRNA is transported and translated from 
hnRNP A2 containing granules.  First, excess premutation transcript may become part of 
hnRNP A2 granules, altering the dynamics of the granule and affecting translation of its mRNAs.  
As part of these granules, excess premutation transcript may affect MBP mRNA translation by 
outcompeting MBP mRNA for access to the granule.  It is also possible that the excess CGG 
repeats may recruit translational activators or repressors to the granule.  Furthermore, recent 
work from the Carson lab has demonstrated that the CGG repeats of the premutation transcript 
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may alter translation by binding to CGG repeats of other mRNAs in a granule that encode 
proteins which regulate translation (personal communication with Dr. John H. Carson).  Through 
this mechanism, the expression of translational regulators in hnRNP A2 granules would be 
altered in FXTAS.  This would affect the translation of all RNAs found in hnRNP A2 containing 
granules, including MBP mRNA.  It is also plausible that due to binding to the excess 
premutation transcript, hnRNP A2 may become sequestered in complexes containing 
premutation transcript and not be able to be present in granules.  In Chapter 3, work is 
presented in which we investigated the presence of expanded CGG repeat RNA, as found in the 
fragile X premutation, in hnRNP A2 containing granules.  Data is also presented in that chapter 
on the translation of MBP mRNA in the presence of expanded CGG repeat RNA. 
A further possibility is that the presence of the premutation transcript does not affect specifically 
MBP mRNA translation but rather the overall health of the OLG.  For instance, mitochondrial 
dysfunction has been identified in the CNS of FXTAS patients and this could eventually affect 
overall OLG function (Ross-Inta et al., 2010).  Changes in OLG health and function could lead to 
demyelination or hinder the ability of the OLG to remyelinate and result in white matter lesions 
found in FXTAS.   
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Tumor Overexpressed Gene (TOG) 
TOG is a 218 KDa protein that is encoded by the cytoskeleton associated protein 5 (CKAP5) 
gene and is ubiquitously expressed in all tissues, with highest expression in the brain.   
Homologues of TOG are present in every eukaryotic organism that has been investigated (Gard 
et al., 2004).  There are two isoforms of TOG, ch-TOG and TOG2, which differ by 60 amino 
acids.  TOG2 is the only isoform expressed in OLGs and neurons (Kosturko et al., 2005).  TOG 
and its homologues are microtubule binding plus end tracking proteins which positively regulate 
microtubule growth.  Under usual conditions, TOG catalyzes the addition of tubulin dimers to the 
growing plus end of microtubules, though in certain circumstances TOG can catalyze 
microtubule shrinkage (Widlund et al., 2011; Brouhard et al., 2008).  TOG is most commonly 
known for its crucial role in centrosome and microtubule stabilization and spindle assembly 
during mitosis (Cassimeris and Morabito, 2004; Gergely et al., 2003; Lee et al., 2001; Charrasse 
et al., 1998).  Because of this function of TOG it is necessary for embryonic development.  This 
is evident in that crosses of TOG heterozygous mice produced no TOG null pups out of 33 pups 
examined from 7 litters (Barbarese et al., 2013).   
TOG is a protein which contains multiple TOG domains, there is evidence that there are 
between 5 and 7 TOG domains (personal communication with Dr. John H. Carson ; Hood et al., 
2013; Andrade et al., 2001).  The C-terminus also contains a sequence for the binding of the 
TACC domain of proteins (Lee et al., 2001).  Each TOG domain consist of 6 HEAT (huntingtin, 
elongation factor 3, the PR65/A subunit of protein phosphatase 2A, and the lipid kinase Tor) 
repeats, which are known to mediate important protein-protein interactions (Andrade et al.,  
2001).   
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TOG and RNA granules 
In OLGs, as in other cell types, TOG associates with microtubules, and immunostaining showed 
that TOG colocalized with cytoplasmic linker protein 115 (CLIP 115), a protein preferentially 
located at microtubule plus ends (Kosturko et al., 2005).  In neurons and OLGs, TOG interacts 
with hnRNP A2 in granules.  TOG’s interaction with hnRNP A2 was first suspected when a 
yeast two-hybrid screen performed to identify the partners of hnRNP A2 from a human brain 
cDNA library revealed the longer isoform of TOG (TOG2) as a binding partner.  This binding 
was confirmed by the co-immunoprecipitation of TOG2 and hnRNP A2 both in vitro and in B104 
cells (Kosturko et al., 2005).  Immunostaining for TOG and hnRNP A2 revealed they do indeed 
interact in OLGs as the two proteins colocalize in 90% of granules examined in the medial and 
distal OLG processes and the proteins are present in a defined stoichiometry.   
HnRNP A2 granules also contain MBP mRNA and the effects of TOG on MBP mRNA transport 
and translation have been examined.  Knockdown of TOG, using shRNA, in maturing cultured 
OLGs showed no MBP expression when examined by immunostaining.  However, expression of 
MOG, which does not contain an A2RE, was unaffected (Francone et al., 2007).   This suggests 
that decrease in MBP expression was not in the inability of the OLG to differentiate but 
specifically in the ability of the cell to express MBP, as MOG is expressed in the late stages of 
OLG differentiation (Fig. 1-2).  Though the translation of MBP mRNA was inhibited, 
immunostaining for hnRNP A2 and in situ hybridization for MBP mRNA revealed no differences 
in the location or amount of granules in the OLGs in which TOG was knocked down (Francone 
et al., 2007).  To examine if TOG’s influence on translation is specific to hnRNP A2 granules 
TOG was knocked down in B104 cells and the translation of microinjected GFP RNA with and 
without a functional A2RE was analyzed.  The knockdown led to decreased GFP expression of 
A2RE-GFP RNA but did not alter the expression of GFP RNA containing a mutated A2RE that 
inhibits the binding of hnRNP A2.   The experiments of Francone et al., (2007) imply that TOG, 
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through binding to hnRNP A2, is necessary for proper translation of MBP mRNA but not for 
granule formation or transport.   These findings led to the creation of mouse models with 
reduction in TOG expression to examine the role of TOG in vivo.   
 
 
 
Figure 1-8:  Transport of MBP mRNA in hnRNP A2 granules.  In OLGs, MBP mRNA is 
transported on microtubules in hnRNP A2 granules, which also contain TOG.  Enlarged image 
displays RNAs, including MBP mRNA, and one TOG protein with 7 TOG domains each bound 
to hnRNP A2 in a granule found in the OLG process (image provided by Dr. John H. Carson).   
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Examining TOG’s function through mouse models 
 
CNP TOG cKO 
The effects of TOG on MBP expression previously described led our lab to investigate the 
consequences of conditionally knocking out TOG in OLGs.  To achieve this goal, floxed TOG 
animals were created by introducing a lox P site into intron 3 and a frt-PGKNeo-frt-loxP cassette 
in intron 6 of the CKAP 5 gene that encodes TOG (Barbarese et al., 2013).  These mice were 
crossed with mice in which the Cre recombinase sequence was placed downstream of the CNP 
promoter, replacing the CNP gene (Lappe-Siefke et al., 2003).  Offspring with both TOG alleles 
floxed and containing the gene for Cre recombinase downstream of the CNP promoter were 
analyzed and termed CNP TOG cKO.  CNP is expressed exclusively in myelinating cells, OLGs 
(CNS) and Schwann Cells (PNS) (Sprinkle, 1989).  CNP is the earliest myelin specific protein to 
be expressed, in vivo  its expression in rodents precedes that of MBP by two to three days 
(Reynolds and Wilkin, 1988).  Therefore, the CNP TOG cKO animal has normal expression of 
TOG in all cell types except for OLGs and Schwann cells.  TOG was knocked out using the 
CNP promoter because knockout of TOG in OLG precursor cells (OPCs) earlier in development 
would probably affect their proliferation and process elongation, due to TOG’s role in mitosis 
and in regulating microtubule dynamics.  This would make it more difficult to specifically 
examine TOG’s influence on MBP mRNA translation as myelin and MBP expression in those 
animals would most likely be altered by changes to OPC proliferation and process elongation.  
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CNP TOG cKO preliminary data 
Analysis of the CNP TOG cKO revealed the animals contain 20% of the control level of MBP at 
approximately two months of age.  Importantly, the quantity of MBP transcript in CNP TOG cKO 
is the same as in wild type mice, supporting the work by Francone et al. (2007) that TOG affects 
MBP mRNA translation.  Levels of MOG, a myelin specific protein expressed at late stages of 
OLG maturation, are decreased to a level of 80% of control.  This slight decrease reveals that in 
TOG’s absence the OLG is still able to differentiate.  The change in MOG levels may not be 
directly due to the absence of TOG, but due to the lack of expression of MBP, as the shiverer 
mouse (discussed on page 18) contains only 30% the amount of MOG as controls.  The 
decrease in MBP and MOG is not due to a decrease in OLGs.  Expression of additional myelin 
proteins were examined and are presented in Chapter 4.  Staining in the corpus callosum for the 
OLG lineage cell marker Olig2 revealed similar levels of Olig2+ cells in the CNP TOG cKO as in 
control.  As previously described, TOG is a microtubule associated protein and MBP mRNA 
requires intact microtubules for transport.  Therefore MBP translation may be altered due to 
changes in microtubule dynamics caused by the absence of TOG.  To estimate microtubule 
dynamics, the microtubule-dependent movement of mitochondria in the processes of cultured 
OLGs was measured by monitoring the velocity of fluorescent live mitochondria.  Preliminary 
data shows decreased mitochondrial movement in the CNP TOG cKO, indicating altered 
microtubule dynamics. 
Examination of the optic nerve revealed that 25% of CNP TOG cKO axons were myelinated, as 
compared to approximately 100% of controls.  No differences in the axon diameter were present 
in the CNP TOG cKO when compared to control.  This indicates that the hypomyelination in 
these animals is not due to axonal defects, but lies in the inability of the OLG to produce myelin.  
An increase in gliosis is also present in theTOG cKO.  This is probably due to the decrease of 
MBP and the resulting hypomyelination, as gliosis is present in young adult shiverer 
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(Westenbroek et al., 1998).  Changes in PNS myelin were evaluated by electron microscopic 
examination of the sciatic nerve.  No differences in the number of myelinated axons or the 
thickness of the myelin sheaths were observed in the CNP TOG KO.  This is due most likely to 
the diminished role of MBP in PNS myelin formation.  Behavior tests of the CNP TOG cKO 
revealed severe deficiencies in motor functions using the rotorod apparatus and measuring the 
gait and stride.  Similar locomotion, strength, and coordination abnormalities are seen in the 
shiverer mouse, evidence that these changes are due to hypomyelination.  It is important to 
note that in the CNP TOG cKO, one CNP allele has been replaced by the gene that encodes 
the Cre recombinase.  This reduction of CNP probably does not contribute significantly to the 
phenotypes found in the CNP TOG cKO as mice that do not express CNP develop normally and 
overall myelin structure and MBP level are unaffected in those mice (Lappe-Siefke et al., 2003).  
TOG +/null 
The TOG +/null animal has only one wild type CKAP5 allele (Barbarese et al., 2013).  Deletion 
of one CKAP5 allele is not conditional and therefore is present in all cells and every cell type 
throughout development in the TOG +/null.  The deletion leads to decreased amounts of TOG, 
which are ~ 55% of control levels.  A complete knockout of TOG in humans would likely be 
embryonic lethal because of the role of TOG in mitosis.  However, there are cases where the 
level of TOG may be reduced.  The TOG +/null is a model that can be used to study such 
situations.  One such situation is when the expression of the microRNA miR-155 is increased.  
TOG/CKAP5 mRNA is a target of the microRNA miR-155, which inhibits its translation (Lossner 
et al., 2011).  Elevated levels of miR-155 may therefore lead to reduction in TOG expression 
under certain conditions.  This could occur in the brains of Down’s syndrome patients, which 
overexpress miR-155 (Wang et al., 2013).  MiR-155 expression may also increase during 
inflammation and is increased in brains of multiple sclerosis patients (Junker et al. 2009).  TOG 
expression may also be decreased in some cases of Potocki-Shaffer syndrome.  Potocki-
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Shaffer syndrome results from a large multi-genes deletion on chromosome 11.  In some cases 
the deletion encompasses the CKAP5 gene which results in TOG haploinsufficiency.  Those 
individuals with a deletion that encompasses the CKAP5 gene show increased cognitive 
disability when compared to those without the deletion, suggesting that a reduction in TOG may 
negatively affect cognitive abilities (Swarr et al., 2010).   
Preliminary data show that MBP levels are decreased by approximately 40% in the brain of the 
+/null mouse.  The rotorod test and analysis of the gait and stride of the TOG +/null revealed no 
substantive changes in their motor behaviors despite the decrease in MBP.  In work presented 
in Chapter 4, we have measured the level of MBP transcripts, the expression of other myelin 
proteins, gliosis, the migration and proliferation of OLG lineage cells, and mitochondria 
movement in OLGs in the +/null mice to characterize the effects of TOG on MBP expression 
and brain development.    
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Chapter 2:  FMRP and myelin protein expression in oligodendrocytes 
 
This chapter is a duplicate version of a published manuscript: 
Giampetruzzi A, Carson JH, Barbarese E. FMRP and myelin protein expression in 
oligodendrocytes. Mol Cell Neurosci. 2013 Sep;56:333-41 
A.G., J.H.C., and E.B. designed the study; A.G. performed the experiments; A.G. analyzed the 
data; A.G. wrote the manuscript with modifications provided by E.B. 
 
Abstract 
 Fragile X syndrome (FXS) is caused by lack of expression of fragile X mental retardation 
protein (FMRP), the product of the Fmr1 gene.  In many cases FXS is associated with 
abnormalities in CNS myelination.  Although FMRP is expressed in oligodendrocyte progenitor 
cells and immature oligodendrocytes (OLGs) previous studies have not detected it in mature, 
myelin-producing OLGs.  FMRP represses translation of myelin basic protein (MBP) RNA in 
vitro and is believed to prevent premature MBP expression in immature OLGs.  Lack of FMRP 
in FXS could lead to premature myelination and/or myelin abnormalities.  Here we show that 
FMRP is expressed in mature, MBP-positive OLGs of rodents and in MBP-positive human 
OLGs.  We confirm that FMRP is a translational repressor of MBP mRNA in vitro, but at 
concentrations likely too high to be physiologically relevant in vivo.  We find MBP expression in 
cultured Fmr1 KO OLGs to be similar to wild type, and expression of MBP and other myelin 
proteins in brain homogenates of the Fmr1 KO mouse to be similar to wild type before, during, 
and after the period of active myelination.  These results suggest that while FMRP is expressed 
in mature OLGs, myelin abnormalities caused by lack of FMRP expression in FXS are not 
recapitulated in rodents. 
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Introduction 
Fragile X syndrome (FXS) is a protein loss-of-function disorder caused by lack of expression of 
the fragile X mental retardation protein (FMRP), the product of the Fmr1 gene.  FMRP is an 
RNA binding protein that regulates translation of several mRNAs in vivo and in vitro 
(Laggerbauer et al., 2001 and Li et al., 2001).  In neurons, several FMRP target RNAs encode 
synaptic proteins which may explain why FXS is associated with behavioral and cognitive 
abnormalities (Schapiro et al., 1995).  Differences in white matter in FXS have been found using 
diffusion tensor imaging (DTI) and magnetic resonance imaging (MRI).  These include both 
increases and decreases in white matter volume along with increased number of myelinated 
nerve fibers (Barnea-Goraly et al., 2003, Haas et al., 2009 and Hoeft et al., 2010).  These 
abnormalities may contribute to some of FXS symptoms since they affect regions or pathways 
in the brain that are involved in aspects of behavior or cognition that are altered in FXS 
(Hallahan et al., 2011 and Hoeft et al., 2011). 
Neuronal structure and function are affected by the lack of FMRP in FXS (Irwin et al., 2001) and 
in the Fmr1 KO mouse, a model of FXS (Huber et al., 2002).  Astrocyte function is also thought 
to be altered in the Fmr1 KO (Jacobs et al., 2010).  Therefore, myelin abnormalities in FXS 
patients could be due to altered signaling by neurons and/or astrocytes to oligodendrocytes 
(OLGs).  Alternatively, primary dysfunction of OLGs could also lead directly to abnormalities in 
myelin composition and/or function.  Dysregulated translation of myelin basic protein (MBP) 
mRNA in the absence of FMRP could affect OLG function, especially during the period of 
neonatal brain development since MBP is essential for the proper formation of CNS myelin 
(reviewed in Boggs, 2006).  FMRP has been detected in rodent oligodendrocyte progenitor cells 
(OPCs) and immature OLGs (Pacey and Doering, 2007 and Wang et al., 2004).  Fmr1 mRNA 
has also been detected in the corpus callosum of adult mouse brain, though the cell type 
expressing Fmr1 mRNA was not identified (Hinds et al., 1993).  A putative role for FMRP in 
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regulating MBP expression has been suggested by several studies.  FMRP binds MBP mRNA 
both in vivo and in vitro and inhibits MBP mRNA translation in vitro (Darnell et al., 2011, Li et al., 
2001 and Wang et al., 2004).  In addition, the N20.1 OLG cell line that accumulates FMRP and 
MBP transcripts does not express MBP, and in the CG4 OLG cell line, FMRP expression 
declines concomitantly with differentiation into MBP-positive cells.  Furthermore, FMRP 
expression is reported to diminish during OLG maturation and previous studies did not detect 
FMRP in MBP-positive OLGs either in vivo or in culture.  These results have been interpreted to 
indicate that FMRP represses translation of MBP mRNA in immature OLGs during normal 
neonatal brain development and that decrease of FMRP allows translation of MBP mRNA in 
mature OLGs later in development (Wang et al., 2004). 
If FMRP regulates MBP mRNA translation, MBP expression may be altered in FXS and in the 
Fmr1 KO mouse, especially early in development.  Changes in MBP expression and myelination 
early in development, even if later rectified, could significantly modify neuronal transmission in 
the Fmr1 KO mouse and FXS, which could contribute to the observed behavioral and cognitive 
deficits (The Dutch-Belgian Fragile X Consortium, 1994).  Even changes in MBP expression that 
do not lead to gross changes in myelin morphology could lead to altered myelin function (Martin 
et al., 2006).  In this study we investigate the expression of FMRP in mature OLGs, the role of 
FMRP in regulating MBP mRNA translation, and the expression of MBP and other myelin 
proteins in the Fmr1 KO mouse. 
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Results 
FMRP is expressed in mature, MBP-positive OLGs in culture 
Developmental expression of FMRP and MBP during OLG lineage progression was analyzed by 
Western blotting.  FMRP was not detected at day 1, when the majority of cells were OPCs 
(Fig. 1A), but was detected at days 3 and 5, when mature OLGs differentiate, and was present 
at a similar level at both time points (Fig. 1A).  MBP was detected at day 5 but not at day 1 or 3. 
These results indicate that FMRP expression does not decline as cells progress from immature 
OLGs to mature MBP-positive OLGs in culture.  Immunocytochemistry verified that at day 5 the 
majority of cells in culture were mature, MBP-positive OLGs with membranous sheets (Fig. 1B). 
The presence of FMRP in mature OLGs was confirmed by immunocytochemistry in both mouse 
and rat cultures. FMRP antibody (Abcam 17722) specificity was validated by positive staining of 
OLGs from wild type (WT) (Fig. 1C) and absence of signal in Fmr1 KO derived OLGs (Fig. 1D), 
as well as by Western blot analysis of homogenates from cerebrums of WT and Fmr1 KO (data 
not shown).  Immunocytochemistry revealed co-localization of FMRP in MBP-positive cells in 
both WT mice and rat OLG cultures (Fig. 1C and E–E″, respectively).  Quantification of FMRP 
immunostaining intensity in rat OLG cultures (Fig. 1E) showed no significant difference between 
mature, MBP-positive OLGs and immature, MBP-negative OLGs (Fig. 1F).  These results 
indicate that in culture FMRP is expressed in mature rodent OLGs at levels exceeding those in 
OPCs and similar to those in immature OLGs. 
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Figure 2-1: FMRP is expressed in mature, MBP-positive OLGs.  (A)  Western blots of rat 
OLG cultures and densitometric analysis of FMRP levels at 1 day (D),3D and 5D in culture. 
Values were standardized to β-actin and means normalized to 3D. There is no significant 
differences in levels of FMRP between 3D and 5D (n = 2, mean ± sem.; t-test, p > 0.05).  (B)  
TO-PRO-3 (green), MBP (red) immunostaining of rat OLGs 5 days in ODM. Scale bar, 20 μm.  
(C, D)  Immunocytochemistry for FMRP (green) and MBP (red) in WT (C) and Fmr1 KO (D) 
OLGs.  Scale bar, 20 μm.   (E–E″)   Immunocytochemistry for FMRP (green) (E) and MBP (red) 
(E′) in immature and mature rat OLGs in culture; merge (E″) Scale bar, 20 μm.  (F)  
Densitometric analysis of FMRP staining intensity (%) (mean ± s.e.m) in cultured rat OLGs, 
normalized to the intensity of MBP negative OLGs. There is no significant difference in FMRP 
staining intensity between MBP negative OLGs (n = 11) and MBP positive OLGs (n = 11). (t-
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test, p > 0.05).  (G-G‴)  Immunohistochemistry of P10 WT mouse corpus callosum with anti-
FMRP (green) (G), anti-MBP (red) (G′), and anti-CNP (blue) (G″); merged images (G‴). Scale 
bar, 20 μm.  (H–H″)  Immunohistochemistry of P24 WT mouse corpus callosum with anti-FMRP 
(green) (H) and anti-MBP (red) (H′); merged images (H”). Scale bar, 20 μm.  (I–I″, J–J″) 
Immunohistochemistry of the subplate region of human 22 week old gestational tissue with anti-
FMRP (green) (I, J) and anti-MBP (red) (I′, J′); merged images (I″,J″). Scale bar, 10 μm. 
 
FMRP is expressed in mature, MBP-positive OLGs in vivo 
The presence of FMRP was also analyzed in OLGs of the corpus callosum in mice. 
Immunohistochemistry at P10 revealed that 2′,3′-cyclic nucleotide-3′-(CNP) and MBP-positive 
OLGs are FMRP-positive (Fig. 1G–G‴).  FMRP expression remained in MBP-positive OLGs at 
P24, which is during the peak period of myelination (Fig. 1H–H″).  FMRP was also found in 
CNP-positive OLGs in adult mice (data not shown).  Although FMRP was detected in MBP-
positive OLGs, its level in OLGs was significantly lower than in neurons in adjacent cortex and 
hippocampus (data not shown).  FMRP expression in OLGs in humans was also examined by 
immunohistochemistry of 22 week old gestational tissue.  We found FMRP to be present in 
human MBP-positive OLGs of the subplate region (Fig. 1I–I″ and J–J″).  These results indicate 
that FMRP expression by MBP-positive OLGs occurs in vivo and is not restricted to rodents. 
FMRP is present in granules containing MBP mRNA 
MBP mRNA is localized in OLG processes and their membranous sheets (Amur-Umarjee et al., 
1997 and Colman et al., 1982).  It is transported to these locations as a component of RNA 
granules and is translated within or in proximity of individual granules (Ainger et al., 1993).  If 
FMRP inhibits translation of MBP mRNA, it is likely present in the same RNA granules as MBP 
mRNA.  To examine this possibility, co-localization of MBP mRNA and FMRP was analyzed in 
rat OLGs microinjected with Cy5-UTP labeled MBP mRNA, which assembles into granules 
(Ainger et al., 1993).  Following microinjection, cells were incubated at 37 °C overnight and then 
fixed and immunostained for FMRP.  The staining intensity of FMRP in the cell body was too 
49 
 
high to resolve individual granules or to assess co-localization with MBP mRNA.  However, 
individual granules were resolved in the cell processes.  Examination of the processes of 
microinjected cells revealed that 14.6 ± 3.7% (mean ± s.e.m.) of granules containing labeled 
MBP mRNA also contained FMRP.  Some FMRP-positive and MBP mRNA-positive granules 
are identified with arrows in magnified views of the processes to the right of Fig. 2A–A″.  These 
results indicate that FMRP is localized in a small subset of MBP mRNA containing granules, 
where MBP translation occurs. 
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Figure 2-2: FMRP localizes to granules and inhibits translation of MBP RNA in vitro. 
(A–A″)  Immunocytochemistry of rat OLGs for FMRP (green) (A) and microinjected Cy5-UTP 
labeled MBP RNA (red) (A′); merged image (A″). Cell processes are magnified (right panels) 
and show granules positive for both FMRP and MBP mRNA (arrows). Scale bar, 20 μm; scale 
bar for A″ enlarged images, 1 μm.  (B, C)  Translation of 8 nM Venus-MBP RNA in wheat germ 
lysate was measured every ten minutes for 130 min using FCS. Translation was monitored by 
measuring the photon count rate after Venus excitation.  (B)  Photon count rates for each 
condition at 130 min (mean ± s.e.m) (n = 3 for all conditions except: + BSA [n = 2], and + 21–
46 nM FMRP [n = 4]); means were normalized to the mean count rate of Venus-MBP without 
FMRP addition. FMRP significantly inhibits the translation of Venus-MBP mRNA at 
concentrations greater than 168 nM (one-way ANOVA followed by LSD test, *p < 0.05).  (C) 
Example of Venus-MBP RNA translation profiles in the presence of increasing concentrations of 
FMRP monitored at 10 min intervals.  
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MBP RNA translation in vitro is inhibited at high concentrations of FMRP 
In vitro translation of Venus-MBP mRNA (full length rat MBP mRNA encoding 14 kDa MBP 
fused to Venus fluorescent protein) was analyzed in the presence of various concentrations of 
human FMRP.  The concentration of Venus-MBP mRNA (8 nM) in the in vitro translation mixture 
is similar to the estimated concentration of endogenous MBP mRNA in individual granules in 
vivo and to the concentrations of other RNA in granules in neurons (Tatavarty et al., 2012).  In 
vitro translation of Venus-MBP was monitored at 10 min intervals for 130 min by fluorescence 
correlation spectroscopy (FCS).  FMRP significantly inhibited translation of Venus-MBP mRNA 
at concentrations > 168 nM but not at lower concentrations (Fig. 2B).  A dose-dependent 
inhibition profile is shown in Fig. 2C.  These results confirm previous findings (Li et al., 2001) 
that FMRP inhibits MBP mRNA translation in vitro. However, in our experiments a 12 fold molar 
excess of FMRP to MBP mRNA is required to inhibit translation, suggesting that this may not be 
physiologically relevant in vivo. 
MBP expression in cultured Fmr1 KO OLGs is similar to WT 
If FMRP regulates translation of MBP mRNA in vivo, OLGs from the Fmr1 KO mouse may 
express MBP earlier or may accumulate more MBP than their WT counterparts.  OLG cultures 
derived from Fmr1 KO and WT mouse brains were used to investigate these possibilities.  In 
4 day old cultures both genotypes had a similar percentage of Olig2-positive cells (a marker for 
all cells in the OLG lineage) that were MBP-positive (Fig. 3A and C).  Densitometric analysis of 
the MBP-immunostained cells showed no differences in the level of MBP per cell in WT and 
Fmr1 KO OLG cultures (Fig. 3B and D).  These results show that the absence of FMRP does 
not accelerate or increase accumulation of MBP in OLGs in culture, suggesting that FMRP does 
not regulate MBP translation in mouse OLGs. 
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Figure 2-3: MBP expression in OLG cultures from Fmr1 KO is similar to WT.  (A)  OLG 
cultures derived from WT and Fmr1 KO were fixed after 4 days in ODM and immunostained for 
Olig2 and MBP. Scale bar, 20 μm.  (B)  Immunocytochemistry for MBP in WT and Fmr1 KO 
OLGs at 2 days and 4 days in ODM. Scale bar, 20 μm.  (C)  Average of the percentage of 
Olig2+ cells that are MBP+ per culture after 4 days in ODM (n = 3 cultures per genotype). There 
is no significant difference in the percentage of MBP+ cells in the Fmr1 KO when compared to 
WT (t-test, p > 0.05).  (D)  The intensity of MBP staining (mean ± s.e.m.) of OLGs at 2D (n = 15 
cells from 1 culture for WT, n = 13 cells from 1 culture for KO) and 4D (n = 38 cells from 4 
cultures per genotype) is not significantly different in OLGs derived from WT and Fmr1 KO at 
either time point (t-test, p > 0.05). 
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MBP expression is normal in Fmr1 KO mouse brain 
Although FMRP does not appear to regulate MBP expression directly in rodent OLGs in culture 
(Fig. 3), its absence in other neural cell types in the Fmr1 KO CNS could lead to changes in 
expression of MBP and/or other myelin proteins.  Using surface plasmon resonance (SPR) 
immunoassay, levels of MBP in cerebral hemisphere homogenates from Fmr1 KO and WT were 
examined before the peak of myelination, at post-natal days 8, 12, and 15.  MBP antibody was 
immobilized on a C5 sensor chip and homogenate from the cerebral hemispheres was flowed 
onto it.  The concentration of MBP in homogenates from WT and Fmr1 KO was negligible at P8, 
2 nmol/g total protein at P12, and approximately 9 nmol/g total protein at P15 (Fig. 4A).  To 
verify the validity of the SPR immunoassay in detecting MBP, the association and dissociation 
binding rates of the homogenates were compared to those of purified MBP and found to be 
similar (Fig. 4B).  In addition, homogenate from the cerebral hemispheres of homozygous 
shiverer mice, which do not express MBP, was used as a negative control and showed only 
minimal binding (Fig. 4B).  Western blots performed on homogenates of cerebral hemispheres 
from Fmr1 KO and WT during the active period of myelination (P21) and after active myelination 
(6 weeks, 5 months) revealed no significant differences in the total amount of MBP in WT and 
the Fmr1 KO (Fig. 4C).  These results indicate that the absence of FMRP does not significantly 
affect MBP expression in mouse CNS, despite the presence of neurons and astrocytes that 
could potentially modulate the myelin expression program. 
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Figure 2-4:  FMRP does not affect the in vivo accumulation and translation of MBP.  (A) 
Accumulation of MBP (mean ± s.e.m.) in the cerebral hemispheres of P8 (n = 2 for WT, n = 3 for 
KO), P12 (n = 3 for WT, n = 3 for KO), and P15 (n = 3 for WT, n = 3 for KO) mice measured by 
SPR does not significantly differ at any time point between genotypes (t-test, p > 0.05)  (B) The 
specificity of the SPR immunoassay for quantifying MBP was validated by measuring the 
association and dissociation rates of antigen binding from brain homogenates as compared to 
purified MBP and by examining the binding of brain homogenate from shiverer mice.  (C)  MBP 
Western blots of brain cerebrum homogenates at time periods during and after the peak of 
myelination (mean ± s.e.m.) (n = 6 WT, 5 KO at 21 days, n = 3 WT, 3 KO at 6 weeks, n = 6 KO, 
5 WT at > 5 months). Values were standardized to β-actin and means normalized to WT at each 
time point. There is no significant difference at any time point in levels of MBP between WT and 
Fmr1 KO (t-test, p > 0.05).  (D)  Percentage of Cy5-UTP labeled MBP mRNA granules that 
translate Venus-MBP in granules with and without positive staining for endogenous FMRP at 2–
3 DIC (n = 9 cells from 2 cultures) and 5–7 DIC (n = 11 cells from 2 cultures).  (E)  Translation 
output per cell (Venus-MBP intensity/labeled MBP mRNA intensity) from granules identified as 
translation positive. For each cell, the average translation output per granule (mean ± s.e.m.) 
was normalized to the average output from FMRP-negative granules. No significant difference 
in translation output was found when comparing translation positive granules with and without 
FMRP at both time points (t-test, p > 0.05, n = 9 cells from 2 cultures for 2–3 DIC, n = 10 cells 
from 2 cultures for 5–7 DIC).  (F)  FCS photobleaching analysis of Venus-FMRP in granules 
(n = 82 granules) of cultured Fmr1 KO OLGs (n = 7) and of Cy5-Venus MBP mRNA in granules 
(n = 47 granules) of cultured shiverer OLGs (n = 7) was used to determine the concentrations of 
FMRP (mean ± s.e.m.) and MBP mRNA (mean ± s.e.m.) in granules. 
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MBP mRNA translation in granules is not affected by FMRP in cultured OLGs 
The comparable accumulation level of MBP in the Fmr1 KO and WT, both in culture and in vivo, 
suggests that FMRP does not significantly inhibit MBP mRNA translation in OLGs in vivo.  To 
investigate whether the presence of FMRP in MBP mRNA granules affects translation in OLGs, 
cultured rat OLGs were microinjected with Cy5-UTP labeled Venus-MBP mRNA.  In these 
experiments, the fluorescent dye Cy5 served as a reporter for the localization of injected MBP 
mRNA in granules, while newly-synthesized fluorescent Venus fusion protein served as a 
reporter for MBP mRNA translation.  Sixteen hours following injection, cells were fixed and 
immunostained to detect the presence of FMRP.  The cells were examined by fluorescence 
microscopy to visualize Cy5-UTP-labeled Venus-MBP mRNA and the newly synthesized MBP 
(Venus-MBP) in individual granules.  Analysis of translation output was done in morphologically 
well-resolved granules present in the OLG processes as seen in Fig. 2A”.  Translation output of 
MBP mRNA from FMRP positive and FMRP negative granules was measured by determining 
the fluorescence intensity of the reporter Venus in each granule.  The value obtained for a 
granule was normalized to the amount of MBP mRNA present as determined by the 
fluorescence intensity of Cy5-UTP in that same granule.  To examine if FMRP's effect on 
translation differs depending on the developmental stage of the OLG, analysis was performed at 
two time periods, at 2 and 3 DIC, when endogenous MBP mRNA is below its peak, and at 5–7 
DIC, when MBP mRNA expression is at peak levels (Strait et al., 1997).  The percentage of 
granules expressing Venus-MBP was not significantly different between FMRP-positive and 
FMRP-negative granules at either time point (Fig. 4D).  Furthermore, the level of translation was 
not significantly affected by the presence of FMRP in the granule (Fig. 4E).  These results 
suggest that FMRP does not regulate MBP mRNA translation in cultured OLGs irrespective of 
their degree of maturation.  This may occur because the amount of endogenous FMRP in 
individual granules is insufficient to inhibit MBP RNA translation. 
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To examine this possibility, the concentration of FMRP in individual granules was measured 3 h 
after Venus-FMRP mRNA was injected into Fmr1 KO OLGs.  In the absence of endogenous 
FMRP, the amount of Venus-FMRP per granule provides an exact measure of total FMRP in the 
granules because all the FMRP in the granule comes exclusively from translation of the 
exogenous FMRP mRNA.  FCS-photobleaching analysis was performed to determine the 
amount of Venus-FMRP in individual granules.  The FCS observation volume was positioned to 
encompass a single granule and the decay in photon counts was measured as fluorescent 
FMRP in the immobile granule was photobleached.  To calculate the concentration of Venus-
FMRP per granule, the number of photon counts per granule was divided by the number of 
photon counts per Venus-FMRP molecule, previously determined by FCS of Venus-FMRP in 
solution.  The average concentration of Venus-FMRP per granule is 13 nM (Fig. 4F). It should 
be noted that this concentration was not limited by the amount of Venus-FMRP present in the 
cell which was in excess.  Next, the concentration of MBP mRNA per granule was measured in 
a similar way by FCS-photobleaching analysis in shiverer OLGs (which lack endogenous MBP 
mRNA) after injection of Cy5-UTP labeled MBP mRNA.  The average concentration of MBP 
mRNA per granule is 5 nM (Fig. 4F).  Thus the molar ratio of FMRP to MBP mRNA per granule 
in cultured OLGs (FMRP/MBP mRNA = 2.6), where FMRP does not inhibit MBP RNA 
translation, is much lower than the molar ratio (FMRP/MBP mRNA > 12) needed to inhibit MBP 
mRNA translation in vitro.  This suggests that the amount of FMRP per granule may not be 
sufficient to inhibit MBP RNA translation in OLGs. 
Expression of other myelin proteins in the Fmr1 KO is similar to WT 
Proteolipid Protein (PLP) mRNA is an FMRP target in vitro and in vivo (Darnell et al., 
2011 and Wang et al., 2004).  Dysregulated expression of PLP, a major component of CNS 
myelin, could like MBP result in myelin abnormalities.  The level of PLP in Fmr1 KO and WT 
brain homogenates, as well as that of other important CNS myelin components, CNP, myelin 
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associated glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (MOG), was 
determined by Western blot.  No differences were observed in the level of PLP, MAG or MOG 
during myelin formation in the brain (21 days) or at any later times examined (PLP, MAG, MOG, 
and CNP) (Fig. 5A–D). 
 
 
 
Figure 2-5: Levels of myelin proteins are similar in WT and Fmr1 KO during and after the 
peak of myelination.  Western blots of brain homogenates at time periods during and after the 
peak of myelination.  (A) MAG (n = 2 WT, 3 KO at 21 days, n = 2 WT, 3 KO at 6 weeks);  (B) 
MOG (n = 2 WT, 4 KO at 21 days, n = 2 WT, 3 KO at > 5 months);  (C) PLP (n = 2 WT, 2 KO at 
21 days, n = 2 WT, 2 KO at > 5 months);  (D) CNP (n = 4 WT, 4 KO)  Values were standardized 
to β-actin and means normalized to WT at each time point.  There are no significant differences 
in levels of the myelin proteins between Fmr1 KO and WT at any of the time points 
(mean ± s.e.m.; t-test, p > 0.05). 
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Discussion 
It has previously been reported that FMRP is expressed in OLG progenitors and in immature 
OLGs, but not in mature MBP-positive OLGs.  The decline in FMRP expression in mature OLGs 
was interpreted to indicate that FMRP inhibits MBP mRNA translation in immature OLGs, and 
that its absence in mature OLGs allows translation of MBP mRNA to proceed (Wang et al., 
2004).  Our results do not support this interpretation.  Firstly, we detected FMRP expression in 
mature OLGs both in culture and in vivo.  This finding is not specific to rodents as FMRP was 
detected in MBP-positive OLGs in human tissue.  Secondly, we found that FMRP levels do not 
decrease as OLGs mature into MBP expressing cells in culture.  Thirdly, we showed that FMRP 
has no effect on MBP mRNA translation in cultured OLGs and overall on MBP expression in the 
rodent brain.  Interestingly, we found that the level of PLP, whose mRNA is reported to be a 
target of FMRP, was also unaffected in Fmr1 KO CNS. 
Presence of FMRP in mature OLGs is consistent with the finding that Fmr1 RNA is present in 
the adult mouse corpus callosum (Hinds et al., 1993).  That study did not identify the cell type 
harboring the transcripts, but our results suggest that at least some of these cells could be 
OLGs.  The low level of FMRP present in OLGs as compared to that of nearby cortical neurons 
could be due to the correspondingly low level of Fmr1 transcripts found in the corpus callosum 
(Hinds et al., 1993).  The discrepancy between our results and previous reports in detecting 
FMRP in mature OLGs could be related to the use of an antigen retrieval method and an anti-
FMRP antibody different than the ones used in previous studies. 
Although FMRP is present in mature OLGs, its concentration may be too low to inhibit overall 
expression of some of its target mRNAs, including MBP and PLP.  Examination of the intensity 
of FMRP immunostaining in mouse brain tissue indicates that FMRP levels in neurons of the 
cortex and hippocampus exceed the levels in OLGs, a finding similar to that reported for human 
59 
 
tissue (Devys et al., 1993).  We have determined that the average concentration of FMRP in 
granules in cultured OLGs is approximately 3 times greater than that of MBP mRNA. However, 
> 12 fold molar excess of FMRP over MBP mRNA is necessary to inhibit translation in vitro. 
In their study, Li et al. (2001) report that in vitro translation of MBP mRNA is inhibited by an 
equimolar concentration of FMRP.  Differences in the in vitro translation protocol used may 
contribute to the differences in our results.  We used a wheat germ lysate translation system 
while Li et al. (2001) used a rabbit reticulocyte lysate.  One important distinction between the 
two systems is that rabbit reticulocyte lysate contains endogenous FMRP, while wheat germ 
lysate does not (Bardoni et al., 1999).  This may have increased the actual concentration of 
FMRP in the Li et al. (2001) system by up to two fold.  In addition, we did not pre-incubate MBP 
mRNA with FMRP.  Pre-incubation of FMRP with target mRNA prior to its addition to the 
translation system has been demonstrated to significantly increase the degree of translation 
inhibition caused by FMRP (Li et al., 2001).  Pre-incubation with FMRP prevents FMRP from 
binding to other components of the translation system and also gives FMRP access to MBP 
mRNA not bound by any ribonucleoproteins that may influence FMRP's ability to bind to MBP 
mRNA and inhibit its translation.  Furthermore, our translation protocol used concentrations of 
MBP mRNA similar to the concentration found in granules from which MBP mRNA is translated 
in vivo. With the caveat that no in vitro translation system can exactly model in vivo situations, 
we believe that our experimental procedure more closely reflects the action of FMRP on MBP 
mRNA translation in vivo.  Failure of FMRP to inhibit MBP mRNA translation in culture may also 
be due to its phosphorylation state in OLGs.  Work done with neurons indicates that 
phosphorylated FMRP can inhibit translation while dephosphorylated FMRP cannot (Ceman et 
al., 2003 and Narayanan et al., 2007).  The phosphorylation state of FMRP under basal 
conditions in OLGs is not known. 
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Though the timing and the level of MBP accumulation do not appear to be regulated by the 
presence of FMRP in OLGs under normal conditions, the presence of FMRP in mature OLGs is 
significant.  It suggests that FMRP may not regulate translation of all the RNAs to which it binds. 
In addition, Fmr1 gene expression may play a role in other neurological disorders. For example, 
Fragile X Tremor Ataxia Syndrome (FXTAS) is a disorder thought to arise from a toxic gain of 
function of Fmr1 mRNA.  Primary dysfunction of OLGs could contribute to the demyelination 
found in FXTAS when Fmr1 mRNA is expressed in OLGs. 
Our study is the first to examine myelin proteins in the Fmr1 KO mouse.  In addition to the 
expression of MBP and PLP, other myelin components investigated were found to be unaffected 
in the cerebral hemispheres of the Fmr1 KO.  The possibility remains that brain region-specific 
differences in myelin are present that could not be detected by our assays or that proteins, other 
than myelin specific proteins, that are involved in lipid metabolism for example, are affected and 
results in subtle changes in myelin structure.  However, our results and the results of the DTI 
study of myelin in the P30 Fmr1 KO (Ellegood et al., 2010) suggest that major CNS myelin 
specific proteins are unaffected in the Fmr1 KO.  The fact that myelin abnormalities are 
observed in FXS suggests that FMRP may play a more significant role in regulating expression 
of MBP and other myelin proteins in humans than in rodents or that myelin abnormalities found 
in FXS patients are due to other factors in addition to the absence of FMRP. 
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Experimental methods 
Animals 
Mice: C57/Bl6 Fmr1 knockout mice (Fmr1 KO) were generously provided by Dr. William 
Greenough (University of Illinois, Urbana, IL) and maintained at the University of Connecticut 
Health Center (Greenough et al., 2001).  Wild type mice of the same strain were obtained from 
the Jackson Laboratories and used as control.  Shiverer mice (C3Fe.SWV-Mbpshi/J, stock # 
001428) were also obtained from the Jackson Laboratories.  Untimed pregnant Sprague Dawley 
rats were obtained from Charles River Laboratories.  Procedures for animal use were approved 
by the Animal Care Committee of the University of Connecticut Health Center and followed 
federal guidelines for research with animals. 
Fluorescence correlation spectroscopy in vitro translation (FCS-IVT) 
Wheat germ lysate translation system (Promega), human recombinant FMRP (Origene, 
TP322699, 21–185 nM), and bovine serum albumin (BSA) (120–200 nM) were used in the in 
vitro translation assay. FCS-IVT was performed as described by Tatavarty et al. (2012).  The 
lysate was centrifuged (10,000 ×g, 30 min) to remove fluorescent particulate material prior to 
the addition of other components.  FMRP was added to the cleared lysate followed by addition 
of Venus-MBP mRNA. Reactions were carried out in a 96 well glass bottom dish.  Newly 
synthesized Venus-MBP protein molecules were detected by FCS using a Zeiss Confocor 3 
system with a 40 ×, 1.2 NA water immersion objective. FCS measurements of total photon 
counts in each well were taken at 10 minute intervals for 130 min. 
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Culture: mouse oligodendrocytes 
P0–P2 mice were sacrificed and mixed glia cultures were prepared from cerebral cortices as 
described by O'Meara et al. (2011).  Cells were plated in T-75 flasks coated with poly-l-Lysine 
(0.1 mg/mL in borate buffer).  Cortices from 3 to 4 mice were used per flask.  The cells were 
grown in 10% fetal bovine serum/DMEM-F12 containing antibiotic and antimycotic mixture 
solution (Gibco 15420).  OPCs were mechanically harvested and plated in growth medium on 
poly-l-Ornithine (.05 mg/mL in borate buffer) coated coverslips for 90 min.  After attachment the 
growth medium was replaced with OLG differentiation medium (ODM) [2 mM GlutaMAX-I 
supplement (Gibco 35050), 30 ng/mL T3 (Sigma T6397) and 2% B-27 Supplement (Gibco 
17504-044) in Neurobasal medium (Gibco 21103-049)] containing antibiotic and antimycotic 
mixture solution (Gibco 15420). 
Rat oligodendrocytes 
Primary glia cultures were prepared from the brains of rats at postnatal days 1–3 and OLGs 
were isolated from these cultures as described by McCarthy and de Vellis (1980).  OLGs were 
plated on poly-l-Ornithine (.05 mg/mL in borate buffer) coated coverslips or tissue culture dishes 
in the same ODM as for mouse OLGs. 
Immunocytochemistry 
Cells grown on coverslips were washed two times with PBS, fixed in 4% paraformaldehyde in 
PBS for 20 min and rinsed 3 times with PBS.  Cells were then permeabilized with 0.5% NP-40 
for 1 min and rinsed with PBS 3 times.  Cells were incubated in blocking buffer (10% goat serum 
in PBS) for 20 min followed by a solution of primary antibody diluted in blocking buffer for 
30 min.  After several rinses, secondary antibodies diluted in blocking buffer were added for an 
additional 30 min.  After removal of the secondary antibodies, coverslips were washed 3 times 
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with PBS and covered with Prolong gold anti-fade reagent.  All steps were performed at room 
temperature. Primary antibodies included rabbit anti-FMRP (1:1000, Abcam 17722), rat anti-
MBP (1:500, Millipore 386), mouse anti-CNPase (1:200, Sigma C5922) and rabbit anti-Olig2 
(1:250, Millipore 9610).  Fluorochrome-conjugated secondary antibodies were from Molecular 
Probes (Carlsbad, CA). TO-PRO-3 staining (1/500) (Invitrogen) was also performed on select 
coverslips. 
Immunohistochemistry 
Mouse brains were fixed in 4% paraformaldehyde overnight and immersed in 30% sucrose in 
PBS overnight at 4 °C.  Brains were then frozen at − 80 °C and 30 μm slices were cut and 
attached to coated microscope slides.  Antigen retrieval was performed by microwave heating 
tissue for 25 min in 0.01 M citrate acid buffer, pH 6.3.  Immunohistochemistry was performed as 
described by Morgan et al. (1992).  Human brain tissue (22 week old) fixed in 4% 
paraformaldehyde in 0.1 M PBS, pH 7.4, overnight and sectioned on a cryostat was obtained 
from the laboratory of Dr. Nada Zecevic.  Antigen retrieval was performed on the tissue by 
microwave heating tissue for 25 min in 0.01 M citrate acid buffer, pH 6.3.  Tissue was washed 
with PBS and blocked for 1 h with blocking buffer (1% Tween-20, 1% BSA, and 10% normal 
goat serum in PBS).  Following blocking, primary antibodies diluted in blocking buffer were 
added to tissue overnight.  Tissue was then washed with PBS and the appropriate secondary 
antibodies diluted in PBS were added for 2 h.  Primary antibodies used were rabbit anti-FMRP 
(1:1000, Abcam 17722) and rat anti-MBP (1:500, Millipore 386).  Secondary conjugated 
antibodies were from Molecular Probes (Carlsbad, CA). 
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Generation of Venus-MBP expression vector 
This vector was obtained from Dr. Victor Francone (Quinnipiac University).  Rat MBP cDNA was 
PCR amplified using the primers: forward 5′-GCGAGATCTATGGCATCACAGAAGAGACCCTC-
3′; reverse: 5′-CGCCCCGGGCAAGTTTATTATTTTTATTTC-3′, which contain the Bgl II and 
SMA I restriction sites respectively.  MBP DNA fragment was ligated into pEGFP-C1 (Clontech, 
Mountain View, CA) using Bgl II and SMA I restriction sites.  GFP cDNA was replaced by Venus 
cDNA using modified restriction-free cloning (Geiser et al., 2001).  Venus cDNA fragment was 
PCR amplified using the following primers: forward 5′-CACCA TGGTGAGCAAGGGCGAGGA-
3′; reverse: 5′-CTTGTACAGCTCGTCCATGC-3′. Venus PCR amplification product was gel 
purified and used in a linear amplification reaction with recipient MBP pelf-CI plasmid under the 
following conditions: denaturing at 95 °C for 30 s followed by 18 cycles of 30 s at 95 °C, 30 s at 
55 °C, and 12 min at 68 °C, all in a final volume of 50 μl.  Two and a half units of Pfu Turbo DNA 
polymerase were used for elongation.  After amplification the methylated parental plasmid was 
digested with 10 U DpnI at 37 °C for 2 h. TOPO competent cells were transformed with a 2 μl 
aliquot of the reaction mix, and positive clones were confirmed by sequencing. 
Venus-FMRP expression Vector 
Obtained from Dr. John H. Carson (UCHC) (Tatavarty et al., 2012). 
Synthesis of RNA 
Venus-MBP mRNA was synthesized by in vitro transcription of linearized template DNA, capped 
and polyadenylated using mScript Kit (Epicentre) according to the manufacturer's protocol. 
Fluorescently labeled RNA was prepared by addition of Cy5-conjugated UTP (Amersham 
biosciences) to the transcription reaction in a 5:3 ratio with unlabeled UTP.  The resulting RNA 
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was purified by precipitation with 5 M ammonium acetate and ethanol, and was dissolved in 
RNAse free water. 
Microinjection 
Cy5-UTP labeled Venus-MBP RNA (1 mg/mL) was injected into the perikaryon of cultured rat 
OLGs as described previously (Ainger et al., 1993), with the exception that cells remained in 
ODM during injection.  Following injection at room temperature, cells were returned to incubate 
at 37 °C until fixed for immunocytochemistry or analyzed by FCS-photobleaching. 
Image analysis 
To measure staining intensity, images of immunostained OLGs were analyzed using Adobe 
Photoshop.  To quantify MBP staining intensity of OLGs from Fmr1 KO and WT cultures each 
cell of interest was outlined using the wand function after determining threshold between the 
interior and exterior of the cell.  The mean intensity inside the selected area was determined 
using the histogram command.  The mean intensity of background outside the OLG was 
subtracted from the mean intensity inside the OLG to give the mean intensity value of MBP 
staining.  The average of the mean intensity of MBP staining for WT cells was normalized to 
100% MBP staining intensity.  For analysis of FMRP levels in non-MBP expressing and MBP 
expressing rat OLGs, FMRP staining intensity was measured in non-MBP expressing OLGs and 
MBP expressing OLGs from the same culture as described above for MBP.  The average FMRP 
staining intensity of the non-MBP expressing OLGs was normalized to 100%. 
Translational output of Cy5-UTP labeled Venus-MBP mRNA in FMRP positive and FMRP 
negative granules was determined using Image J.  A circle encompassing an area of 1.56 μm2 
was positioned with Cy5-UTP labeled Venus-MBP mRNA at the center.  The intensity of Cy5 
and of Venus was measured in the delineated area and a ratio of Venus to Cy5 was calculated 
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for each granule.  The average ratio of Venus to Cy5 for granules without FMRP (FMRP 
negative) was normalized to a translational output of 1 for each cell. 
Surface plasmon resonance (SPR) immunoassay 
SPR measurements were performed using the BiacoreT100 system (GE Healthcare) as 
described in Rich and Myszka (2007).  Ligand consisting of rat antibody to MBP (Millipore MAB 
386, 1:80 in sodium acetate, pH 4.5) was immobilized on a CM5 sensor chip (Biacore) at a 
concentration corresponding to 6000 resonance units (RUs).  Analyte consisting of purified 
bovine MBP (Sigma M1891) diluted in HEPES buffered saline buffer (10 mM HEPES, 3 mM 
EDTA, 0.25 M NaCl, and 0.05% surfactant p20, pH 7.5) or cerebral hemisphere homogenate 
(0.4 mg/mL to 2.2 mg/mL) diluted in HEPES buffered saline buffer was injected over the sensor 
surface at a flow rate of 30 μL/min for 180 s.  The RU values increased as MBP analyte binds to 
antibody ligand.  Post-injection dissociation was monitored for 180 s at a flow rate of 30 μL/min. 
The surface was regenerated between injections with 10 mM glycine-HCl (pH 2.0) at a flow rate 
of 30 μL/min for 10 s.  The concentration of MBP in each homogenate sample was calculated 
based on the maximum RU minus the background for shiverer homogenate, which lacks MBP. 
Purified bovine MBP analyte was used as a standard to determine the molar MBP concentration 
in cerebral hemisphere homogenate samples.  Using the MBP molar concentration and total 
protein concentration for each homogenate, the concentration of MBP per gram of total protein 
for each homogenate was calculated. 
Western blots 
All samples were homogenized in 0.3 M Sucrose/50 mM Tris–HCI, pH 7.5.  Samples used to 
detect PLP were not heated.  Samples used to detect MAG were electrophoresed under non-
reducing conditions.  All samples were run on 12% polyacrylamide/Bis–Tris gels and transferred 
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electrophoretically onto Immobilon-P membranes (Millipore, Bedford,MA).  Immunodetection 
was performed with: mouse anti-MBP (SMI-94 Covance, 1:3000), rat anti-MBP (Millipore 386, 
1:3000), mouse anti-PLP (Millipore maB 388, 1:3000), mouse anti MAG (Millipore mab 1567, 
1:3000), mouse anti-MOG (Millipore mAB 5680, 1:3000), mouse anti-β-actin (Sigma A5441, 
1:5000), mouse anti-GAPDH (Millipore MAB 374, 1:5000),and appropriate secondary antibodies 
conjugated to peroxidase.  Western blots were visualized using chemiluminescence detection 
(Pierce). 
Fluorescence correlation spectroscopy (FCS)-photobleaching 
To perform FCS-photobleaching of granules, Venus-FMRP mRNA or Cy5-UTP labeled Venus-
MBP mRNA (1 mg/mL) was microinjected into the perikaryon of OLGs.  After microinjection, 
cells were returned to 37° for 3 h.  FCS was performed using a Zeiss Confocor 3 system with a 
63 ×, 1.4 NA oil immersion objective.  FCS-photobleaching was then performed by positioning 
the FCS observation volume to encompass individual immobile fluorescent granules in the 
microinjected OLGs.  The observation volume was excited with the proper wavelength of light 
for the granule being analyzed (488 nm for Venus-FMRP RNA, 633 nm for Cy5-UTP labeled 
Venus-MBP mRNA) for 10 s, which lead to photobleaching of the granule.  The photon count 
rate decay throughout the 10 s was recorded.  Subtracting the photon count rate after 
photobleaching from the count rate before photobleaching provided the total photon count rate 
per granule.  To determine the number of molecules per granule, the total photon count rate per 
granule was divided by the photon count rate per molecule of RNA or protein determined by 
FCS of the labeled RNA or labeled protein in solution in a 96 well glass bottom dish.  The 
number of molecules per granule was then converted to concentration by dividing the number of 
molecules per granule by the volume of the FCS observation volume. 
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Abstract  
The fragile X premutation transcript, with expanded CGG repeats, is found at elevated levels in 
fragile X-associated tremor/ataxia syndrome (FXTAS).  Altered translation of MBP mRNA 
caused by the fragile X premutation may contribute to the white matter pathology present in 
FXTAS.   The effect of the fragile X premutation transcript on translation of myelin basic protein 
(MBP) mRNA was examined in oligodendrocytes and fibroblasts.  Due to its expanded CGG 
repeats, which bind to hnRNP A2, the fragile X premutation was hypothesized to be present in 
MBP mRNA containing granules, where it could affect the translation of MBP mRNA.  We found 
that indeed RNA with expanded CGG repeats can be present in granules with MBP mRNA.  
The presence of the expanded CGG repeat RNA in OLGs was found to increase translation of 
microinjected MBP mRNA in granules.  In addition, increased translation of microinjected MBP 
mRNA was observed in fibroblasts from FXTAS individuals when compared to controls.  Taken 
together these results imply that the presence of the fragile X premutation transcript may 
increase the translation of MBP mRNA in individuals with FXTAS.   
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Introduction 
The fragile X premutation is present when the FMR1 gene contains between 55 and 200 CGG 
repeats (Cornish et al., 2009).  Individuals with the fragile X premutation have increased levels 
of FMR1 mRNA and normal to slightly reduced levels of FMRP (Peprah et al., 2010; Tassone et 
al., 2000).  Approximately 20% of female premutation carriers are diagnosed with premature 
ovarian insufficiency and approximately one third of all premutation carriers have symptoms of 
FXTAS by the age of 50 (Oostra and Willemsen, 2009).  The presence of FMR1 mRNA in 
intranuclear inclusions, increased levels of FMR1 mRNA, and slight or no change in the level of 
FMRP in FXTAS patients has led to the belief that mRNA toxicity is the cause of the 
neurological deficits associated with the fragile X premutation. 
The expanded number of CGG repeats is believed to be the source of the toxicity in premutation 
RNA.  The number of CGG repeats correlates with the severity of motor dysfunction, the age of 
onset of tremor and ataxia, the number of intracellular inclusions, and the age of death of 
FXTAS patients (Leehey et al., 2008; Tassone et al., 2007; Greco et al., 2006).  Also, the 
presence of an expanded number of CGG repeats without the remainder of the FMR1 gene is 
toxic to cells both in vitro and in vivo (Hashem et al., 2009; Handa et al., 2005; Jin et al., 2003).  
The predominant hypothesis is that the CGG repeats induce their toxicity by sequestration of 
proteins that perform important functions in the cell.  Intranuclear inclusions in FXTAS and in 
cells with expanded CGG repeat RNA independent of the FMR1 transcript contain various RNA 
binding proteins that have significant roles in the cell.  Overexpression of some of these 
sequestered proteins can suppress the neurodegenerative phenotype in Drosophila models with 
expanded CGG repeat RNA (Sellier et al., 2010; Jin et al., 2007; Sofola et al., 2007; Iwahashi et 
al., 2006).  Another emerging hypothesis is that repeat-associated non-AUG-initiated (RAN) 
translation of polyglycine from expanded CGG repeat RNA in the cells can also be toxic (Todd 
et al., 2013).   
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A novel hypothesis has been proposed that CGG repeat RNA in FXTAS may alter translation of 
mRNAs containing the A2 Response element (A2RE) (Dr. John H. Carson and Rene Norman, 
personal communication).  The A2RE sequence is a sequence for which heterogeneous 
ribonucleoprotein A2 (hnRNP A2) has high affinity (Hoek et al., 1998).  The binding of hnRNP 
A2 to A2RE mRNAs allows those mRNAs to assemble into hnRNP A2 containing granules in 
the cell body and travel to their destination, either dendrites or OLG processes, to be translated 
(Munro et al., 1999; Hoek et al., 1998; Ainger et al., 1997).  Expanded CGG repeat RNA has 
also been demonstrated to bind to hnRNP A2, and expanded CGG repeats have an increased 
binding affinity (Sofola et al., 2007).  The presence of expanded CGG repeat RNA in hnRNP 
A2/RNA granules may alter translation of A2RE mRNAs in the same granules.  Proteins whose 
RNAs contain A2RE sequences include activity regulated cytoskeletal-associated protein 
(Arc), Cam Kinase II, and myelin basic protein (MBP) (Gao et al., 2008; Ainger et al., 1997).   
Preliminary evidence suggests that the translation of Arc mRNA is decreased in the presence of 
expanded CGG repeats (personal communication, Rene Norman), supporting the hypothesis 
that expanded CGG repeats can affect the translation of A2RE containing mRNAs.   
White matter disease is prevalent in individuals diagnosed with FXTAS (Garcia-Arocena and 
Hagerman, 2010a; Cohen et al., 2006).  Though no intranuclear inclusions have been identified 
in oligodendrocytes (OLGs) in this disorder, it is possible that altered translation of MBP mRNA 
from hnRNP A2/RNA granules contributes to the white matter disease (Greco et al., 2002).  
Altered translation of MBP mRNA occurring during development, during myelin maintenance, or 
during remyelination in response to injury could all lead to the white matter disease present in 
FXTAS.  In this work we investigated if the presence of expanded CGG repeat RNA affected the 
translation of MBP mRNA.  This was performed by examining the translation of microinjected 
Venus-MBP mRNA in rat OLGs coinjected with 99 CGG repeat RNA and in fibroblasts of 
FXTAS patients.   
72 
 
Results 
CGG repeat expansion RNA is found in MBP mRNA granules 
CGG repeat RNA is capable of binding to hnRNP A2 (Sofola, 2007).  MBP mRNA is transported 
and translated in hnRNP A2 containing RNA granules (Munro et al., 1999; Hoek et al., 1998; 
Ainger et al., 1997).  Therefore, we examined if expanded CGG repeat RNA is present in 
granules containing MBP mRNA.  Labeled RNA containing 99 CGG repeats (Cy3-UTP 99 CGG 
repeat) was coinjected into mature rat OLGs with differentially labeled MBP mRNA (Cy5-UTP 
Venus-MBP mRNA).  Cy3-UTP 99 CGG repeat RNA was found in granules in the cellular 
processes.  It colocalized with Cy5-UTP Venus-MBP mRNA in a population of granules, 67% of 
labeled MBP mRNA granules also contained labeled 99 CGG repeat RNA (n = 108) and 94% of 
labeled CGG 99 repeat RNA granules also contained labeled MBP mRNA (n=77) (Fig. 3-1 A-E).  
Injection of Cy3-UTP RNA with an identical sequence to 99 CGG repeat RNA, but with no CGG 
repeats (0 CGG repeat RNA), was diffuse and did not form granules or colocalize with Cy5-UTP 
Venus-MBP mRNA. 
 
Expanded CGG repeat RNA does not alter the level of MBP mRNA that localizes in granules 
One mechanism by which expanded CGG repeat RNA could affect granule assembly is by 
outcompeting MBP mRNA for access to the granule.  To examine this possibility we assessed if 
the presence of the 99 CGG repeat RNA altered the quantity of MBP mRNA in granules.  OLGs 
were coinjected with Cy5-UTP Venus-MBP mRNA and either Cy3-UTP 99 CGG repeat RNA or 
Cy3-UTP 0 CGG repeat RNA.  The average intensity of Cy5 in labeled MBP mRNA containing 
granules did not differ between OLGs injected with labeled 99 CGG repeat RNA or labeled 0 
CGG repeat RNA (Fig. 3-1F).  These results indicate that the presence of expanded CGG 
repeat RNA does not affect the level of MBP mRNA that is incorporated into a granule.  
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Figure 3-1:  Expanded CGG repeat RNA increases MBP mRNA translation.  (A-C)  Rat 
OLGs were coinjected with Cy3-UTP 99 CGG repeat RNA (red; A and C) and Cy5-UTP Venus-
MBP mRNA (green; B and C).  Scale bar, 10 μm.   (D)  Higher magnification of area identified in 
C, arrows denote granules in which Cy3-UTP 99 CGG repeat RNA (red) and Cy5-UTP Venus-
MBP mRNA (green) are colocalized (scale bar, 5μm).  (E)  Intensity of Cy5-UTP Venus-MBP 
mRNA and Cy3-UTP 99 CGG repeat RNA in granules of OLGs coinjected with both RNAs.  (F)  
Intensity of Cy5-UTP Venus MBP mRNA in granules from OLGs coinjected with Cy3-UTP 99 
CGG repeat RNA (n = 54 granules from 4 cells) and those coinjected with Cy3-UTP 0 CGG 
repeat RNA (n = 39 granules from 3 cells).  No significant difference was present when 
comparing the intensity of Cy5-UTP in granules coinjected with 99 CGG repeat RNA or 0 CGG 
repeat RNA (mean + s.e.m; Nested ANOVA, p >0 .05).  (G)  Cumulative frequency plot of 
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translation efficiency (Venus Intensity/Cy5 Intensity) in rat OLGs coinjected with Cy5-UTP 
Venus-MBP mRNA and either Cy3-UTP 0 CGG repeat RNA or Cy3-UTP 99 CGG repeat RNA.  
Venus-MBP mRNA translation efficiency is increased in OLGs coinjected with Cy3-UTP 99 
CGG RNA when compared to OLGs coinjected with Cy3-UTP 0 CGG repeat RNA (Kolmogrov-
Smirnov Test, *p < 0.01). 
 
 
 
Transient presence of expanded CGG repeats increases MBP mRNA translation in OLG 
granules 
 
Microinjected, fluorophore conjugated mRNA is capable of assembling into granules, is properly 
transported, and can be translated (Tatavarty et al., 2012).  To examine if the presence of 
expanded CGG repeat RNA in granules could alter MBP mRNA translation in the same 
granules, translation of Cy5-UTP Venus-MBP mRNA coinjected with Cy3-UTP 99 CGG repeat 
RNA was analyzed and compared to OLGs coinjected with Cy3-UTP 0 CGG RNA.  In these 
experiments, the molar concentration of Cy3-UTP 99 CGG repeat RNA was more than twice 
that of the Cy5-UTP Venus-MBP mRNA injected.  OLGs were fixed 3.5 hours after 
microinjection and the translation efficiency in individual granules was calculated by capturing 
the intensity of the reporter Venus, whose open reading frame (ORF) was 5’ of MBP’s ORF, and 
dividing it by the intensity of Cy5, which labeled MBP mRNA.  Since expanded CGG repeats 
were only present in the OLG for 3.5 hours, differences in MBP mRNA translation would most 
likely be due to effects of CGG repeats on granule translation.  In this short time period, it is 
unlikely that changes in translation would be due to global effects of 99 CGG repeat RNA on the 
cell physiology, such as deterioration in viability or changes in gene expression.  Those OLGs 
coinjected with labeled 99 CGG repeat RNA displayed increased translation of MBP mRNA in 
granules compared to those coinjected with labeled 0 CGG repeat RNA (Fig. 3-1G). 
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Figure 3-2:  Increased translation of Venus-MBP mRNA in FXTAS fibroblasts.  (A)  Venus-
MBP in control fibroblast microinjected with Cy5-UTP Venus-MBP mRNA.  Scale bar, 50 µm.  
(B)   Cumulative frequency plot of translation efficiency (Venus Intensity/Cy5 Intensity) in 
fibroblasts injected with Cy5-UTP Venus-MBP mRNA.  Translation of Venus-MBP mRNA is 
increased significantly between FXTAS 13 and control in high expressing fibroblasts 
(Kolmogrov-Smirnov Test, *p < 0.01).  (C)  Mean translation efficiency of Cy5-UTP Venus-MBP 
mRNA is significantly increased in low expressing fibroblasts of FXTAS 08 when compared to 
controls (t-test, *p < 0.01). 
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FXTAS fibroblasts have increased MBP mRNA translation 
Translation of microinjected Cy5-UTP Venus-MBP mRNA was examined in human fibroblasts 
obtained from several different FXTAS patients (FXTAS 08 and FXTAS 13) and from a control 
individual (control 603).  Though investigation of MBP mRNA translation in OLGs expressing the 
fragile X premutation would be best, we believe fibroblasts are a suitable cell type to study the 
effects of the fragile X premutation transcripts on translation of MBP mRNA.  Fibroblasts contain 
hnRNP A2 and fibroblasts of FXTAS patients express increased amounts of fragile X 
premutation transcript compared to control (Garcia-Arocena et al., 2010b; Zhu et al., 2002).  In 
addition, we found that when microinjected Venus-MBP mRNA was translated, newly 
synthesized Venus-MBP was localized to the membrane (Fig. 3-2A).  This suggests that 
fibroblasts have similar transport and translation mechanisms as OLGs.  Examination of Venus-
MBP mRNA expression five hours after microinjection revealed that FXTAS 13 fibroblasts have 
a statistically significant increase in translational efficiency when compared to control (Fig. 3-
2B).  This increase in efficiency was prevalent in the population of higher expressing fibroblasts.  
Examination of the population of lower expressing fibroblasts, those whose translation was 
below the median, revealed Venus-MBP mRNA expression was increased in the lower 
expressing fibroblasts of FXTAS 08 (Fig. 3-2C).  These results imply that the presence of the 
fragile X premutation in cells can increase the translation of MBP mRNA.    
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Discussion 
Coinjection of labeled MBP mRNA and labeled 99 CGG repeat RNA into OLGs revealed that 
the two RNAs colocalize in many granules.  Interestingly, granules containing only one species 
of labeled RNA have a lower intensity of that labeled RNA than many of the granules containing 
both species of RNA (Fig. 3-1E).   This may occur because granules with only one species of 
labeled RNA detected may be granules which cannot accommodate as much RNA.  Less 
capacity for RNA in these granules may lead to less overall RNA in the granule, perhaps leading 
to the exclusion of a species of RNA.  Decreased concentration of RNA in these granules may 
be due to decreased quantities of hnRNP A2 in the granule.  It is also possible that granules 
with only one species of labeled RNA detected are not granules with decreased accommodation 
for RNA, but are granules in which there is a high level of endogenous, unlabeled RNA.  Though 
the injected OLGs do not have endogenous 99 CGG repeat RNA, they do contain Fmr1 
transcript which does contain CGG repeats.     
Microinjection of MBP mRNA into fibroblasts obtained from both FXTAS patients and a control 
displayed differences in translation of MBP mRNA.  Future experiments should be performed to 
confirm these results.  First, fibroblasts from only one control individual were examined.  It is 
possible that due to other genetic factors fibroblasts from the control individual used in our 
assays may translate more or less than the average population.  An additional caveat in these 
experiments is that because of random X inactivation in female fibroblasts the fragile X 
premutation transcript is presumably expressed in approximately 50% of the FXTAS patient 
derived fibroblasts.  This may have decreased our ability to detect the full extent of the effects of 
the premutation transcript on MBP mRNA translation.  Future experiments should be performed 
with fibroblasts from additional control and FXTAS subjects.  It would be most beneficial to 
perform additional experiments with fibroblasts derived from male patients, so that all FXTAS 
fibroblasts examined express the fragile X premutation.  Ideally, the results of the fibroblast and 
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OLG experiments should also be validated in OLGs derived from iPSCs of FXTAS patients 
and/or in OLGs derived from the FMR1 CGG knock-in mouse, which is a commonly used 
mouse model to study FXTAS (Berman et al., 2009). 
It has been theorized that the expanded CGG repeat RNA of the fragile X premutation transcript 
may bind to other CGG repeat containing RNAs involved in translation regulation, inhibiting their 
translation (Fig. 3-3, Dr. John H. Carson and Rene Norman, personal communication).  Whether 
the expression of inhibitors or enhancers of translation regulation are more affected by the 
presence of the fragile X premutation transcript would determine if the translation of other 
mRNAs, such as MBP mRNA is increased or decreased.   Our results suggest that expanded 
CGG repeat RNA has a greater effect on reducing the translation of mRNA of proteins that 
inhibit MBP mRNA translation.  Arc mRNA, which also has an A2RE sequence, has increased 
translation both in fibroblasts and neurons in the presence of expanded CGG repeats.  If indeed 
CGG repeat RNA of the fragile X premutation transcript binds to and inhibits CGG repeat 
containing RNAs involved in translation regulation, our results imply that different translation 
regulatory proteins control the translation of Arc mRNA and MBP mRNA.     
Overall, the results of our experiments provide evidence that MBP mRNA translation is 
increased by the presence of the fragile X premutation.  In the peripheral nervous system, 
hypermyelination of axons early in development has been found to lead to demyelination later 
on (Adlkofer et al., 1995).  It is possible that in FXTAS the myelin lesions found are due to 
demyelination caused by hypermyelination earlier in life.  Examination of myelin expression in 
the FMR1 CGG repeat knock-in mouse and imaging of youth with the fragile X premutation will 
reveal if hypermyelination contributes to the myelin lesions present in FXTAS.  
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Figure 3-3:  Suggested mechanism by which the fragile X premutation influences the 
expression of proteins which regulate translation.  Expanded CGG repeats in the fragile X 
premutation RNA bind to CGG repeats present in transcripts for proteins which regulate 
translation.  This binding prevents the translation of mRNAs that encode proteins that regulate 
mRNA translation, therefore altering the translation of other mRNAs, such as MBP mRNA.  
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Experimental Methods 
 
Fibroblast Cell lines 
 
Fibroblast cell lines were obtained from Dr. Anita Bhattacharyya at the University of Wisconsin-
Madison.  FX 08-2 (referred to as FXTAS 08 in text and figures) was derived from a female with 
one allele with 31 CGG repeats and one allele with 105 CGG repeats present in the 5’UTR of 
the FMR1 gene.  FX 13-2 (referred to as FXTAS 13 in text and figures) was derived from a 
female with one allele with 33 CGG repeats and one allele with 85 CGG repeats present in the 
5’UTR of the FMR1 gene.  Control 603 was derived from a male whose sole allele contained 31 
repeats in the 5’UTR of the FMR1 gene.  
 
Animals 
Untimed pregnant Sprague Dawley rats were obtained from Charles River Laboratories. 
Procedures for animal use were approved by the Animal Care Committee of the University of 
Connecticut Health Center and followed federal guidelines for research with animals. 
Rat OLGs  
Primary glia cultures were prepared from the brains of rats at postnatal days 1–3 and OLG 
progenitor cells (OPCs) were isolated from these cultures as described by McCarthy and de 
Vellis (1980). OPCs were plated on poly-l-Ornithine (.05 mg/mL in borate buffer) coated 
coverslips in OLG differentiation medium (ODM) [2 mM GlutaMAX-I supplement (Gibco 35050), 
30 ng/mL T3 (Sigma T6397) and 2% B-27 Supplement (Gibco 17504-044) in Neurobasal 
medium (Gibco 21103-049)] containing antibiotic and antimycotic mixture solution (Gibco 
15420). 
81 
 
Venus-MBP expression vector 
 The vector was obtained from Dr. Victor Francone (Quinnipiac University).  Rat MBP cDNA was 
PCR amplified using the primers: forward 5′-GCGAGATCTATGGCATCACAGAAGAGACCCTC-
3′; reverse: 5′-CGCCCCGGGCAAGTTTATTATTTTTATTTC-3′, which contain the Bgl II and 
SMA I restriction sites respectively.  MBP DNA fragment was ligated into pEGFP-C1 
(Clonetech, Mountain View, CA) using Bgl II and SMA I restriction sites.  GFP cDNA was 
replaced by Venus cDNA using modified restriction-free cloning (Geiser et al., 2001).  Venus 
cDNA fragment was PCR amplified using the following primers: forward 5′-CACCA 
TGGTGAGCAAGGGCGAGGA-3′; reverse: 5′-CTTGTACAGCTCGTCCATGC-3′.  Venus PCR 
amplification product was gel purified and used in a linear amplification reaction with recipient 
MBP pelf-CI plasmid under the following conditions: denaturing at 95 °C for 30 s followed by 
18 cycles of 30 s at 95 °C, 30 s at 55 °C, and 12 min at 68 °C, all in a final volume of 50 μl.  Two 
and a half units of Pfu Turbo DNA polymerase were used for elongation.  After amplification the 
methylated parental plasmid was digested with 10 U DpnI at 37 °C for 2 h. TOPO competent 
cells were transformed with a 2 μl aliquot of the reaction mix, and positive clones were 
confirmed by sequencing. 
 
CGG repeat expression vector  
 
Plasmids containing CGG repeats along with firefly luciferase (pT7-FMR1-5’UTR(CGG)n-FL, 
n=0, 30, 62, 99) were gifts from Dr. Michael Fry (Khateb et al., 2007).  Briefly, a T7 promoter 
sequence was ligated to the Blp1 site 235 bases upstream of human FMR1 5’UTR (pE5.1; 
GenBank accession number L29074) fused to firefly luciferase. The CGG repeats were located 
117 bases upstream of the FMR1 ATG initiation codon and a Xho I site was located 
approximately 10 bases after the final CGG repeat (and approximately 60 bases upstream of 
82 
 
the initiation codon).  Pre-transcription, these plasmids were linearized with Xho I, eliminating 
the firefly luciferase reporter sequence. 
 
Synthesis of RNA   
 
Cy5-UTP Venus-MBP mRNA, Cy3-UTP 0 CGG mRNA, and Cy3-UTP 0 CGG mRNA were 
synthesized by in vitro transcription of linearized template DNA.  The DNA was transcribed, 
capped, and polyadenylated using mScript Kit (Epicentre) according to the manufacturer’s 
protocol, with the exception that Cy5-conjugated UTP or Cy3-conjugated UTP (Amersham 
biosciences) were added to the transcription reaction in a 5:3 ratio with unlabeled UTP.  The 
resulting RNA was purified by precipitation with 5 M ammonium acetate and ethanol, and was 
dissolved in RNAse free water.  
 
Microinjection of Rat OLGs 
 
 Cy5-UTP labeled MBP mRNA (0.5 mg/mL) was microinjected into the perikaryon of mature rat 
OLGs in primary cultures at least 5 days in differentiation medium. The Cy5-UTP labeled MBP 
mRNA was coinjected with Cy3-UTP 0 CGG RNA (0.1 to 1 mg/mL) or Cy3-UTP 99 CGG RNA 
(0.1 mg/mL).  Following injection at room temperature, cells were returned to incubate at 37°C 
until fixed 3.5 hours later. 
 
Comparing Cy5-UTP MBP mRNA quantity in granules of RAT OLGs    
 
The quantity of Cy5-UTP labeled Venus-MBP mRNA in granules of microinjected rat OLGs was 
determined using NIH Image J software.   Using the oval tool, the granule was delineated and 
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the intensity of Cy5 enclosed area was measured and the background subtracted.  For OLGs in 
which granules with expanded 99 CGG repeats and without expanded 99 CGG repeats were 
examined from the same cell the average Cy5 intensity of granules without the 99 CGG repeats 
was normalized to 1.  For the experiment in which the concentration of Cy5-UTP MBP mRNA 
from granules of OLGs coinjected with either 99 CGG repeat RNA or 0 CGG repeat RNA were 
compared, the average Cy5 intensity of granules from the 99 CGG repeat RNA was normalized 
to 100%.   
 
Measuring Translation of MBP mRNA in granules of microinjected rat OLGs 
 
Translational output of Cy5-UTP labeled Venus-MBP mRNA in granules was determined using 
Image J.  Using the oval tool, the granule was delineated and the intensity of Cy5 and of Venus 
was measured in the enclosed area and the background subtracted.  The ratio of net Venus 
intensity to net Cy5 intensity was calculated for each granule, and was classified as translational 
output.   
 
Measuring whole cell translation of Venus MBP mRNA in fibroblasts 
  
Cy5-UTP Venus MBP mRNA (0.3 mg/mL or 1 mg/mL) was coinjected into the perikaryon of 
fibroblasts with dextran.  Following injection, cells were returned to incubator at 37°C and 
images were acquired five hours post injection or cells were fixed with 4% paraformaldehyde at 
five hours and images acquired at a later time point.  Cells that were imaged were chosen by 
the detection of dextran in the cell.  Image J was used to analyze the images.  Using the 
polygon tool, the outline of the fibroblast was drawn. The intensity of Cy5 and of Venus was 
measured in the encompassed area and the background subtracted.  The net intensity of Venus 
was used as a measure of translation for the fibroblasts.   
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Abstract  
Knocking out the tumor overexpressed gene (TOG) protein in mouse OLGs results in the near 
absence of myelin basic protein (MBP) and extensive CNS dysmyelination.  We found levels of 
other myelin proteins, proteolipid protein (PLP) and myelin-associated glycoprotein (MAG), to be 
similarly reduced when TOG is knocked out in OLGs.  We also examined TOG heterozygote 
(+/null) mice, which express half the normal level of TOG.  Previously, MBP levels at 90 days 
had been found to be decreased in these mice.  We discovered that MBP levels do not differ 
from wild type in the cerebral hemispheres of TOG heterozygote mice at 22 and 45 days, and 
levels of other myelin proteins also do not differ at 45 days.  This suggests that another 
mechanism, besides the originally proposed decrease in MBP mRNA translation, is the cause of 
MBP deficiencies in the 90 day old TOG heterozygotes.  TOG is a microtubule-associated 
protein and may be necessary for the transport of MBP mRNA granules to the myelin 
compartment where translation occurs.  The effect of the reduction of TOG on microtubule 
based transport was examined by measuring mitochondrial transport.  The transport of 
mitochondria was only slightly altered in the TOG heterozygote.  These results suggest that 
approximately half the amount of TOG allows for sufficient transport of MBP mRNA and proper 
translation of MBP mRNA.    
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Introduction 
In the central nervous system (CNS), myelin basic protein (MBP) is expressed exclusively by 
oligodendrocytes (OLGs), the myelinating cells of the CNS.  MBP is expressed at much greater 
levels in the OLG processes than in the perikaryon, and MBP mRNA preferentially locates to 
OLG processes where it will be translated (Trapp et al., 1987; Colman et al., 1982).  MBP 
mRNA is present in ribonucleoprotein complexes termed granules that move into OLG 
processes by a microtubule-based mechanism.  RNA granules contain molecular motors and 
machinery necessary for protein synthesis (Carson et al., 2001; Carson et al., 1997; Barbarese 
et al., 1995).  MBP mRNA binds to heterogeneous ribonucleoprotein A2 (hnRNP A2) via two 
tandemly duplicated cis- acting sequences termed A2 Response Elements (A2REs) in its 3’ 
UTR (Hoek et al., 1998). This interaction allows MBP mRNA to assemble into hnRNP A2 
containing granules (Munro et al., 1999; Hoek et al., 1998; Ainger et al., 1997).  These granules 
also contain the Tumor Overexpressed Gene (TOG) protein, most likely because TOG binds to 
hnRNP A2 (Kosturko et al., 2005). 
TOG is the product of the Cytoskeleton Associated Protein (CKAP) 5 gene, a single copy gene 
with homologues in species ranging from yeast to vertebrates (Gard et al., 2004).  TOG is a 
microtubule-associated protein most commonly studied in dividing cells for its crucial role in 
centrosome and microtubule stabilization and spindle assembly (Cassimeris and Morabito, 
2004; Gergely et al., 2003; Lee et al., 2001; Charrasse et al., 1998).  An additional role for TOG, 
as a component of hnRNP A2 containing granules in OLGs and neurons, has been uncovered.  
Conditional knockout of TOG in hippocampal neurons led to decreased incorporation of the 
activity-regulated cytoskeleton-associated (Arc) protein mRNA into RNA granules, decreased 
granule transport in dendrites, and decreased translation of Arc mRNA, which contains an 
A2RE sequence (Barbarese et al., 2013; Gao et al., 2008).  In addition, TOG knockdown in 
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B104 cells (a rat neuronal cell line) led to decreased translation of GFP RNA containing an 
A2RE sequence but not of GFP RNA (Francone et al., 2007).    
TOG’s role in OLGs has been examined by knockdown approach, using shRNA, in developing 
OLGs in culture.  TOG knockdown resulted in the absence of MBP expression.  The knockdown 
did not alter the expression of a mature myelin protein, myelin oligodendrocyte glycoprotein 
(MOG), whose mRNA does not contain an A2RE sequence.  The TOG knockdown did not alter 
the ability of MBP mRNA to incorporate into granules and be properly transported, suggesting 
that unlike neurons TOG may only play a role in translation and not granule assembly and 
transport in OLGs (Francone et al., 2007).   
MBP is required for myelin formation in the CNS (Readhead and Hood, 1990). Therefore, we 
have investigated the function of TOG in MBP expression by examining the level of MBP and its 
transcripts and the presence of myelin in animals in which the cre/lox system was used to 
conditionally knockout TOG in OLGs.  Myelin abnormalities in the CNP TOG cKO are obvious 
as mice have chronic intention tremors, seizures, and die prematurely.  Analysis of the CNP 
TOG cKO revealed the animals contain 20% of the control level of MBP at approximately two 
months of age, without a change in MBP transcript level.  Accumulation of MOG, a myelin 
specific protein expressed at late stages of OLG maturation, is decreased to a level of 80% of 
control.  This slight decrease reveals that in TOG’s absence the OLG is still able to differentiate.  
The change in MOG levels may not be directly due to the absence of TOG, but due to the lack 
of expression of MBP, as the shiverer mouse (discussed in chapter 1) contains only 30% the 
amount of MOG as controls.  The decrease in MBP and MOG is not due to a decrease in OLGs.  
Staining in the corpus callosum for the OLG lineage cell marker Olig2 revealed similar levels of 
Olig2+ cells in the CNP TOG cKO as in control.  Changes in microtubule dynamics in the OLG 
may play a role in the decreased expression of MBP, as the TOG CNP cKO exhibits decreased 
mitochondrial movement, suggesting alterations in microtubule dynamics.   
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Preliminary data strongly suggest that complete knockout of TOG is embryonic lethal 
(Barbarese et al., 2013).  In order to examine a situation more applicable to human conditions 
we have investigated MBP expression in the TOG heterozygote (+/null) mouse.  This animal 
possesses 55% of control TOG levels in the CNS.  Because TOG is ubiquitously expressed it is 
assumed that TOG is reduced in all cell types (Gard et al., 2004).  The decline in TOG 
expression is throughout development, unlike in the TOG CNP cKO.  Analysis of MBP levels in 
the TOG heterozygote at 90 days reveals MBP levels ~ 60% of control.  
The objective of the work presented in this chapter was to expand the analysis of OLGs and 
myelination in the CNP TOG cKO and in the TOG heterozygote.  In the CNP TOG cKO, the 
expression of additional myelin proteins was examined.  In the TOG heterozygote, distribution 
and quantity of OLG lineage cells was examined to investigate if a reduction in TOG could affect 
OLGs during development.  In addition, MBP expression was analyzed at time points earlier 
than 90 days and the expression of several other myelin proteins was also examined.  Finally, to 
examine if microtubule dynamics may be altered as in OLGs of the CNP TOG cKO, we 
indirectly studied microtubule dynamics in the TOG heterozygote OLGs by analyzing 
mitochondrial movement.  
Results 
Myelin deficiencies include proteolipid protein (PLP) and myelin-associated glycoprotein (MAG) 
in the CNP TOG cKO 
Previous work performed in our lab found reductions in MBP and MOG in the CNP TOG cKO at 
2 months of age.  Two additional major myelin proteins were investigated, PLP and MAG.  
Significant reductions where present in both of those proteins in the CNP TOG cKO (Fig. 4-1).  
These reductions are most likely secondary to the absence of MBP as reductions in those 
proteins are also found in the shiverer mouse (Shiota et al., 1991; Sheedlo et al., 1986).   
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Figure 4-1:  MAG and PLP levels are decreased in the CNP TOG cKO.  Western blots and 
densitometric analysis of levels of MAG (A) and PLP (B) in homogenates of cerebral 
hemispheres of WT (n = 3) and TOG CNP cKO (n=4) at 2 months of age.  Values were 
standardized to β-actin and means normalized to WT. There are significant differences in the 
levels of MAG and PLP (mean + s.e.m.; t-test, *p< 0.01). 
OLG development is normal in the TOG heterozygote 
Unlike the CNP TOG cKO, TOG is reduced in TOG heterozygote OLGs throughout life.  TOG is 
also reduced in the astrocytes and neurons which signal to OLGs.  These reductions in TOG 
could lead to differences in development of OLGs.  To examine this we computed the density of 
OLG lineage cells in the corpus callosum of the TOG heterozygote at 22 days (D).  OLG lineage 
cells were identified by immunostaining for Olig2 (Fig. 4-2A, B).  There was no significant 
difference in the density of Olig2 cells in the corpus callosum of the TOG heterozygote when 
compared to wild type (WT) (Fig. 4-2C).  We also examined if the quantity of OLG lineage cells 
in the entire cerebral hemispheres differed in the TOG heterozygote by examining the 
expression of Olig2.  Western blots of Olig2 showed no significant differences in expression 
between the TOG heterozygote and WT (Fig. 4-2D, E).  These results suggest that there is 
proper number and proper placement of OLG lineage cells in the TOG heterozygote.  
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Figure 4-2:  The TOG heterozygote displays normal OLG development.  Immunostaining for 
Olig2 in 22 D mouse brains of WT (A) and TOG heterozygote (B).  Corpus callosum (CC) is the 
enclosed region in the image.  Scale bar, 100 µm.  (C)  Average density of Olig2 expressing 
cells in the corpus callosum of WT (n = 2) and TOG heterozygote (n = 2) at 22 D.  There is no 
significant difference in the density when comparing genotypes (mean ± s.e.m.; t-test, p > 0.05).  
(D+E)  Detection of Olig2 in Western blots of brain homogenates from WT and TOG 
heterozygote at 22 D (n = 2 WT, 2 +/null) and 45 D (n = 3 WT, 4 +/null).  Densitometric analysis 
revealed no differences in the expression of Olig2 in the TOG heterozygote when compared to 
WT at either time point (mean ± s.e.m.; t-test, p > 0.05).   Values were standardized to β-actin 
and means normalized to WT at each time point.  
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MBP and other myelin proteins are unchanged in the TOG heterozygote 
Results previously obtained in our lab showed that the level of MBP was reduced in the TOG 
heterozygote at the age of 3 months.  To investigate if the decline in MBP was due to decreased   
expression of MBP during myelination, we examined MBP levels in the cerebral hemispheres 
during (22 D) and shortly after (45 D) the active period of myelination.  MBP levels were found 
to be unchanged at both time points in the TOG heterozygote (Fig. 4-3A).  Levels of other major 
myelin proteins were also examined at 45 D to see if they were altered as in the TOG CNP cKO.  
No significant differences were found in the expression of MOG, MAG, PLP, and CNP (Fig. 4-
3B-E). 
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Figure 4-3:  Levels of myelin proteins are similar to WT in the TOG heterozygote brain at 
22 D and 45 D.   Western blots of homogenates of cerebral hemispheres from WT and TOG 
heterozygote (+/null).  (A)  MBP at 22 D (n = 2 WT, 2 +/null) and 45 D (n = 3 WT, 3 +/null);   (B)  
MOG at 45 D (n = 3 WT, 4 +/null);  (C)  MAG at 45 D (n = 2 WT, 3 +/null);  (D)  PLP at 45 D          
(n = 3 WT, 4 +/null);  (E)  CNP at 45 D (n = 3 WT, 4 +/null)   Values were standardized to β-actin 
and means normalized to WT at each time point.  There are no significant differences in levels 
of the myelin proteins between TOG heterozygote and WT at any of the time points 
(mean ± s.e.m.; t-test, p > 0.05). 
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Mitochondria motility is slightly altered in the TOG heterozygote 
TOG is also a microtubule-associated protein and its absence or reduced level could affect 
microtubule-based transport.  In addition to RNA granules, microtubules are necessary for the 
transport of a variety of components and organelles in the cell.  Mitochondrial motility, which 
was used as an indirect measure of microtubule-based transport of RNA granules, was 
previously found in our lab to be altered in the CNP TOG cKO.  This alteration may contribute to 
a decrease in MBP expression in OLGs from the CNP TOG cKO, as it could alter the transport 
of MBP mRNA on microtubules.  Measurement of mitochondria motility can easily be assessed 
by live cell labeling of mitochondria with a fluorescent compound (Mitotracker, Life 
Technologies) and monitoring them by microscopy.  There was no obvious decline in the 
number of mitochondria found in the processes when comparing the TOG heterozygote and 
WT, suggesting that mitochondria can properly travel out to the processes in TOG heterozygote 
OLGs (Fig. 4-4A, B).  TOG heterozygote mitochondria displayed a small increase (74.3% in 
+/null vs. 71.2% in WT) in frequency of immobility and an increase in displacement in a small 
subset of frames analyzed (Fig. 4-4C).  These results imply there may be a slight change in 
microtubule dynamics in the TOG heterozygote.  However, as MBP expression is unaltered in 
the TOG heterozygote at 45 D it is highly unlikely that these very slight microtubule changes 
influence MBP mRNA transport and translation.  
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Figure 4-4:  Mitochondrial movement is slightly altered in the TOG heterozygote.  WT (A) 
and TOG heterozygote (B) OLGs with mitochondria labeled using Mitotracker.  Scale bar, 20 
µm.  (C)  Cumulative frequency plot of mitochondrial displacement per 5 second frame, the 
distribution of mitochondrial displacement significantly differs in the TOG heterozygote (n = 
11,726 frames from 455 mitochondria) when compared to control (n= 13,774 frames from 400 
mitochondria) (*p < 0.0001, Kolmogorov-Smirnov test). 
  
94 
 
Discussion 
We found that in addition to the changes in MBP and MOG expression in the CNP TOG cKO, 
the expression of the myelin proteins PLP and MAG was also altered at 2 months of age.  
Expression of MBP and other myelin proteins has not been examined at earlier time points in 
the CNP TOG cKO.  However, an intention tremor is present in these mice starting at around 
two weeks, which strongly implies MBP and myelin levels are very low at those early time 
points.  Examination of the TOG heterozygote revealed that despite changes in MBP at three 
months, there is no reduction in MBP at 22 D and MBP or other myelin proteins at 45 D. As 
would be expected with no changes in MBP or myelin proteins, no changes in expression of 
Olig2 or density of OLGs in the corpus callosum were detected in the TOG heterozygote at the 
time points examined. 
 There are several plausible reasons for differences in timing of MBP changes in the CNP TOG 
cKO and the TOG heterozygote.  First, the amount of TOG in the TOG heterozygote OLG may 
be sufficient to support MBP expression at early time periods but not at later time periods.  If the 
expression of TOG in control OLGs decreases over time then similar decreases in the TOG 
heterozygote may leave the OLG with insufficient amounts of TOG for MBP expression for 
myelin maintenance, resulting in decreases in MBP at later time points.  Unlike the CNP TOG 
cKO, TOG is reduced in all cell types in the TOG heterozygote.  It may be possible that the 
amounts of TOG in the OLG are enough for proper MBP expression and myelination, but that 
dysfunction in neurons and astrocytes may occur at later time points leading to decreases in 
MBP levels.  The effects of reducing TOG in astrocytes has not been examined but conditional 
knockout of TOG in hippocampal neurons alters dendritic spine density, reduces LTP, and 
affects behavior (Barbarese et al., 2013).  It is quite possible that the decline in TOG in the TOG 
heterozygote may lead to neuronal changes which then affect MBP expression.  The absence of 
changes in MBP levels in the TOG heterozygote during and soon after the active period of 
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myelination suggests that MBP synthesis and accumulation may not be altered at all in the TOG 
heterozygote, but that its degradation may be increased.   
 Mitochondrial motility is only slightly changed in cultured OLGs of the TOG heterozygote, 
implying that microtubule-based transport is close to normal.  Results of the same assay in CNP 
TOG cKO showed slower transport.  The deficiencies in microtubule-based transport in the CNP 
TOG cKO may contribute to the more severe and earlier MBP and myelin differences in the 
CNP TOG cKO when compared to the heterozygote.  MBP mRNA travels out to the OLG 
process on microtubules making them very important for proper localization of MBP mRNA 
(Ainger et al., 1997).  Further investigation into the localization of MBP mRNA in the CNP TOG 
cKO, such as by in situ hybridization, will help determine the role altered transport of MBP 
mRNA may play in the decreased MBP levels found in the CNP TOG cKO.   
The results of our experiments have expanded the knowledge of how OLGs and the expression 
of MBP and myelin proteins are affected in the CNP TOG cKO and the TOG heterozygote.  
Based on these results, further experiments should be performed to examine if different 
mechanisms lead to MBP decreases in the CNP TOG cKO and the TOG heterozygote. 
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Experimental Methods 
Animals   
Floxed TOG mice and TOG+/null mice were produced at the UCHC Gene Targeting and 
Transgenic Facility (GTTF).  CNP-Cre mice were obtained from Dr. Klaus Nave (Lappe-Siefke 
et al., 2003).  All mice are on a C57/BL6 background. 
Western Blots 
All samples were homogenized in 0.3 M Sucrose/50 mM Tris–HCI, pH 7.5. Samples used to 
detect PLP were not heated.  Samples used to detect MAG were electrophoresed under non-
reducing conditions.  All samples were run on 12% polyacrylamide/Bis–Tris gels and transferred 
electrophoretically onto Immobilon-P membranes (Millipore, Bedford,MA).  Immunodetection 
was performed with: mouse anti-CNP (Millipore mab 326R, 1:5,000), mouse anti-MBP (SMI-94 
Covance, 1:3000), rabbit anti-Olig2 (Millipore mab 9610, 1:5,000), mouse anti-PLP (Millipore 
mab 388, 1:3000), mouse anti MAG (Millipore mab 1567, 1:3000), mouse anti-MOG (Millipore 
mab 5680, 1:3000), mouse anti-β-actin (Sigma A5441, 1:5000), mouse anti-GAPDH (Millipore 
MAB 374, 1:5000), and appropriate secondary antibodies conjugated to peroxidase.  Western 
blots were visualized using chemiluminescence detection (Pierce). 
Immunohistochemistry 
Mouse brains were fixed in 4% paraformaldehyde overnight.  The following day, brains were cut 
into 150 µm thick sections. Brain sections were immunostained by blocking for 2 hours with 
blocking buffer (10% normal goat serum (NGS) and 0.2% Triton X-100 in PBS).  Primary 
antibody (rabbit anti-Olig2, Millipore mab 9610, 1:350) in blocking buffer was added overnight at 
4°C while shaking.  The following day sections were washed three times in PBS for five minutes 
and then the secondary antibody (Molecular Probes, Goat anti-rabbit Alexa 488-A11034, 
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1:1000) was added for 2 hours in PBS.  Sections were then was three times for five minutes 
with PBS and mounted onto microscope slides. 
Computation of Olig2 density in corpus callosum 
Using AxioVision LE software, Olig2 positive cells were counted in enclosed circles, whose area 
were known, that were drawn in the corpus callosum of 150 µm mouse brain slices.  Corpus 
callosum was identified by its position in the slice and the alignment of myelinated fibers.  Brain 
sections at similar depth were examined for WT and the TOG heterozygote.   
Culture: mouse oligodendrocytes 
 
P0–P2 mice were sacrificed and mixed glia cultures were prepared from cerebral cortices as 
described by O'Meara et al. (2011).  Cells were plated in T-75 flasks coated with poly-l-Lysine 
(0.1 mg/mL in borate buffer).  Cortices from 3 to 4 mice per flask were used.  The cells were 
grown in 10% fetal bovine serum/DMEM-F12 containing antibiotic and antimycotic mixture 
solution (Gibco 15420).  OPCs were mechanically harvested and plated in growth medium on 
poly-l-Ornithine (.05 mg/mL in borate buffer) coated coverslips for 90 min.  After attachment the 
growth medium was replaced with OLG differentiation medium (ODM) [2 mM GlutaMAX-I 
supplement (Gibco 35050), 30 ng/mL T3 (Sigma T6397) and 2% B-27 Supplement (Gibco 
17504-044) in Neurobasal medium (Gibco 21103-049)] containing antibiotic and antimycotic 
mixture solution (Gibco 15420). 
Analysis of mitochondrial movement 
Mice OLGs cultured in ODM for 3 to 4 days were analyzed.  ODM was removed and the culture 
dish rinsed several times with DMEM-F12 (Lonza, 12-719F).  Then, 50 µM Mitotracker Red 
CMXRos (Life Technologies) in DMEM-F12 was added to cover the dish and OLGs were 
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incubated for 25 minutes at 37°C.  Following incubation, cells were rinsed several times with 
DMEM-F12 and then left in DMEM-F12 to be imaged.  Live cell imaging was performed by using 
a Carl Zeiss Axiovert 200M microscope equipped with an incubation chamber. The cells were 
kept at 37°C while imaging.  Cells chosen to be imaged were verified as OLGs by morphology, 
and highly branched OLGs appearing to be differentiated were used.  OLGs were imaged every 
5 seconds for up to 5 minutes.    
Mitochondria were tracked as described previously (DeVos et al., 2007).  The absolute velocity, 
regardless of direction, was found for each five second interval for each mitochondria.  Each 
mitochondria was analyzed for between 40 and 59 intervals.  For each mitochondria, the 
frequency of stationary events was computed by dividing the number of intervals without any 
movement by the total number of intervals analyzed.  Also, the average absolute velocity of all 
intervals was found for each mitochondria.  
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Chapter 5:  Future Directions 
Work presented in chapters 2-4 investigated different mechanisms by which MBP expression 
may be altered.  FMRP, a translation inhibitor, was found to have no effect on MBP mRNA 
translation and MBP expression in rodents, and the fragile X premutation mRNA increased 
exogenous MBP mRNA translation in rodent OLGs and human fibroblasts.  These findings lead 
to the need for future work to investigate why myelin abnormalities are found in these disorders.  
Continued investigation of TOG and its role in regulating MBP expression was presented in 
chapter 4.  Though significant amounts of work have been performed in our lab, further work will 
be necessary to identify the mechanism by which a delayed decline in MBP levels occurs in the 
TOG heterozygote, how TOG may affect MBP mRNA translation, and how TOG itself is 
regulated in OLGs.  
Oligodendrocyte differentiation 
Investigation of myelin protein expression in cultured OLGs can be very informative.  Rat 
oligodendrocyte precursor cells (OPCs) can be obtained in great quantities and survive for over 
a week after differentiation.  In contrast, mouse OPCs are obtained in much lower quantities and 
usually do not survive much after differentiation.  Since most disorders are modeled in mice, this 
creates a problem for myelin studies.  I have unsuccessfully attempted to increase the survival 
of mouse OLGs by using several different differentiation media and rat OLG conditioned 
differentiation media.  Future work in the field of OLG studies should focus on a protocol that 
leads to increased survival of mouse OLGs in culture.  A protocol which efficiently produces 
OLGs from human induced pluripotent stem cells (iPSCs) in culture also should be devised.  
Current protocols yield OPCs for injection into mouse brain, but more work needs to be 
performed on determining the conditions for prolonged survival of differentiated OLGs in culture 
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(Wang et al., 2013).  The ability to work with cultured OLGs from human iPSCs from diseased 
and control patients would be very beneficial.     
 
The role of FMRP in OLGs and on myelin protein expression 
Investigating the role of FMRP in OLGs 
As described in chapter 2, we found FMRP to be expressed in cells throughout the OLG 
lineage.  Prior to our work, the proposed role of FMRP in the OLG was to inhibit MBP mRNA 
translation.  However, we found that not to be the case.  Our work leads to the inquiry as to the 
role FMRP in OLGs.  It is possible that FMRP could be involved in MBP mRNA translation 
inhibition, but not under normal conditions because its role is duplicated by other MBP mRNA 
translation regulators.  FMRP has been found to interact with the 3’ UTR of MBP mRNA and 
there are several regulators of MBP mRNA translation that interact with its 3’ UTR.  In a 
situation in which other translational regulators of MBP mRNA are dysfunctional, FMRP may 
have an increased role in inhibiting MBP mRNA translation.  For instance, a reduction in hnRNP 
E1 activity accompanied by reduced FMRP expression may lead to myelin alterations.  To test 
this, a double knockdown of FMRP and hnRNP E1 in cultured rat OLGs could be generated and 
MBP mRNA translation compared to that of control and single knockdowns.  FMRP may also 
function in a role that is independent of translational regulation of MBP mRNA or other myelin 
functions.  For instance, FMRP may be involved in metabotropic support to axons or other OLG 
functions.   
Examining the differential effects of FMRP on myelin 
Myelin alterations are found in FXS patients.  Contrary to what was expected, our examination 
of the Fmr1 KO mouse on the C57/BL6 background revealed no changes in any of the major 
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myelin proteins in the cerebral hemispheres.  Our findings suggest that in addition to the 
absence of FMRP, a genetic or environmental factor, not present in the mice we examined, is 
necessary to cause myelin alterations.  One such factor may be the enriched environmental 
experiences a human is subjected to as compared to laboratory mice.  A future experiment 
would be to compare the myelination of Fmr1 KO and control mice in an enriched environment.  
Rodents in enriched environments have increases in myelin and possibly Fmr1 KO mice may 
have a more drastic myelin increase than control (Zhao et al., 2012).  Examination of myelin in 
humans with FXS would also be very useful in determining which additional factors cause 
myelin changes in FXS, as myelin changes in FXS are not homogenous.  Genomic studies of 
FXS patients with similar myelin phenotypes, based upon MRI, could help decipher any 
potential genetic factors.  In addition, analysis of myelin in FXS patients from similar and 
different environments could help determining the role environmental factors may play on myelin 
in FXS. 
 
Investigating the role of myelin in FXTAS 
Characterizing MBP and myelin protein expression in the CGG knock-in mouse    
Results presented in chapter 3 suggest MBP mRNA translation is increased in the presence of 
the fragile X premutation.  In the peripheral nervous system, hypermyelination in development 
has been found to lead to demyelination later in life (Adlkofer et al., 1995).  In FXTAS, 
hypermyelination due to increased MBP expression may lead to demyelination and the myelin 
lesions present in the disorder.  Investigation of MBP and other myelin proteins in the knock-in 
mouse models in which expanded CGG repeats have been incorporated into the 5’UTR of the 
FMR1 gene should be performed at various time periods to determine if the presence of the 
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fragile X premutation can lead to hypermyelination followed by demyelination (Berman et al., 
2009).   
 If myelin changes are not found in the CGG knock-in mouse, it would suggest that additional 
factors may be necessary for myelin alterations in FXTAS.  Different factors which may lead to 
the white matter phenotype can be investigated in the CGG knock-in mouse.  For instance, 
individuals with fragile X premutation RNA may not remyelinate as well upon insult to myelin.  
This can be examined by subjecting CGG knock-in mice to demyelination and comparing their 
ability to remyelinate to controls.   
Investigating the role of OLGs in FXTAS pathogenesis 
Myelin lesions found in FXTAS may be produced by several different mechanisms.  Primary 
dysfunction in astrocytes and neurons that through secondary effects alters the ability of the 
OLG to properly myelinate, maintain myelin, or remyelinate is one probable cause of white 
matter disease in FXTAS.  In chapter 2, we show that FMRP is expressed in mature OLGs.  
This expression makes it possible for the fragile X premutation to directly affect OLGs, which 
means primary OLG dysfunction may also contribute to the white matter disease present in 
FXTAS.  Further work should be performed to determine which mechanism, or both, cause the 
myelin phenotype in FXTAS. 
Examination of myelination in the CGG knock-in mouse alone will not determine if there is 
primary dysfunction in OLGs in the presence of the fragile X premutation.  It is expected that 
since OLGs express FMRP, they will have elevated levels of fragile X premutation transcript.   
Elevated levels of fragile X premutation transcript in the OLG are most likely needed for primary 
dysfunction of OLGs in FXTAS.  Quantitative PCR of premutation transcript levels in OLGs from 
CGG knock-in mice can be compared to controls.  Increased expression of the premutation 
transcript in CGG knock-in mice would warrant several other experiments to examine if the 
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presence of the fragile X premutation transcript in OLGs affects OLG function.  If myelin 
differences were found in the mouse model, co-cultures of OLGs derived from the CGG knock-
in mouse with wild type neurons can be analyzed to determine if OLGs from the CGG knock-in 
mouse myelinate differently than control OLGs.  In addition, OPCs from the CGG knock-in mice 
can be added to brain slices or transplanted into the brain of shiverer mice and the pattern of 
myelination compared to that of control OPCs.  Shiverer mice do not express MBP and addition 
of exogenous OPCs to brain slices or injection of OPCs into shiverer brain leads to the 
formation of compact myelin (Bin et al., 2012; Najm et al., 2011).  Human OPCs derived from 
iPSCs have also been demonstrated to produce compact myelin and prevent premature death 
when introduced into shiverer brain (Wang et al., 2013).  Myelination and survival of shiverer 
mice injected with OPCs derived from FXTAS patients and controls can also be compared.  
When the protocol has been established for differentiating mature human OLGs from iPSCs in 
culture, examining MBP and myelin in OLG cultures derived from iPSCs of FXTAS patients 
should also be informative.  If these experiments show primary dysfunction in OLGs to be a 
cause of myelin differences in the presence of the fragile X premutation, experiments based on 
Venus-MBP mRNA translation in OLGs with expanded CGG repeats performed in chapter 3 
could be expanded upon.    
TOG in OLGs 
Further analyzing TOG’s effects on MBP and other myelin proteins 
Results in chapter 4 identify reductions in MBP and other myelin proteins in the CNP TOG cKO.   
Decline in the other myelin proteins are thought to be a secondary effect to the severe 
decreases in MBP expression, as expression of these proteins is also reduced in the shiverer 
mouse.  The shiverer mouse does not express MBP due to a mutation in the MBP gene.  To 
verify that MBP reduction is the cause of the changes in other myelin proteins, transcript levels 
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of PLP could be examined in the CNP TOG cKO.  The shiverer mouse has reduced expression 
of PLP transcript at 18 days and a similar reduction in the CNP TOG cKO would verify that at 
least some of the changes in PLP level could be attributed to altered levels of MBP (Shiota et 
al., 1991). 
Investigating the delayed decline in MBP levels in the TOG heterozygote 
Examination of MBP and other myelin proteins in the brain of the TOG heterozygote, which was 
presented in chapter 4, revealed no changes in MBP levels at 22 days and no alterations in 
MBP and other myelin proteins at 45 days.  The absence of changes in MBP is surprising as 
MBP expression has been previously found in our lab to be decreased in the brain of the TOG 
heterozygote at three months.  One important piece of evidence to gather would be if there are 
changes in other myelin proteins at three months in the TOG heterozygote.  This information 
would be useful in determining if the mechanism leading to decreased MBP levels at three 
months is specific to MBP or not.   
The timing of MBP decline in the TOG heterozygote implies that MBP mRNA translation, at 
least during the active period of myelination, is not altered.  This suggests that an alternative 
mechanism may lead to the reduction in MBP in the TOG heterozygote at 90 days.  One 
possible mechanism is increased MBP degradation.  Future work can be performed to 
determine if degradation of MBP and other myelin proteins is increased, both in the TOG 
heterozygote and in the CNP TOG cKO.  The TOG heterozygote features reductions of TOG in 
all cell types.  Sufficient amount of TOG may be present in OLGs for the proper expression of 
MBP at 90 days, but dysfunction in other cell types may be affecting OLG function.  This can be 
investigated by examining MBP and myelin in CNP TOG conditional heterozygotes.  These 
animals are available to be studied in our lab and they have normal expression of TOG in all 
cells of the CNS except OLGs.  
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Confirming the role of the A2RE in TOG’s regulation of MBP mRNA expression 
Though further experiments should still be performed, it is highly probable that TOG specifically 
regulates the translation of MBP mRNA and not of all mRNAs in the OLG.  TOG’s binding to 
hnRNP A2, reduced translation of A2RE containing GFP mRNA but not GFP mRNA in B104 
cells in which TOG has been knocked down, and altered translation of A2RE containing Arc 
mRNA in TOG knockout neurons suggest that the A2RE sequence provides the sensitivity of 
MBP mRNA to TOG reductions (Barbarese et al., 2013; Francone et al., 2007; Kosturko et al., 
2005).  To confirm this, expression of microinjected Venus-MBP mRNA without the A2RE 
sequence could be compared in control OLGs and OLGs with a reduction in TOG.  In this 
instance, we expect the expression of Venus-MBP mRNA without the A2RE sequence to be 
similar to control when TOG is reduced.  Ideally this experiment would be performed in TOG 
CNP cKO and control.  However, microinjection of mouse OLGs has been very difficult when 
compared to rat OLGs, so this experiment may need to be performed in rat OLGs in which TOG 
levels have been decreased through shRNA knockdown.  
Evaluation of expression of other mRNAs with an A2RE in OLGs can also be performed.  One 
of the transcripts for Myelin-associated Oligodendrocyte Basic Protein (MOBP) contains an 
A2RE sequence (Ainger et al., 1997).  It would be very interesting to compare the translation of 
the MOBP transcript containing the A2RE in control OLGs to translation in OLGs where TOG is 
reduced.  Those results can then be compared to the results of analyzing translation of the 
MOBP transcript without an A2RE under the same conditions.  It would be expected that 
translation of the MOBP transcript with the A2RE would be decreased when TOG is reduced in 
the OLG, but no difference should be found in translation of MOBP without the A2RE when 
comparing control with TOG reduced OLGs.  Discoidin domain receptor 1 (Ddr1) is expressed in 
myelin and mouse transcripts for Ddr1 contain an A2RE sequence, as well as do 4 of the 5 
human transcripts (Roig et al., 2012; Roig et al., 2010).  Knockdown of hnRNP A2 in human 
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OLG cell lines showed decreased expression of Ddr1.  It would be interesting to examine levels 
of Ddr1 in the brain of the TOG heterozygote and the CNP TOG cKO.     
Determining the mechanism by which TOG regulates MBP expression 
In vitro assays 
As previously stated, it is highly likely TOG regulates MBP mRNA translation.  However, the 
exact mechanism by which TOG influences MBP mRNA translation has not been determined.  
Several experiments can be performed, both in vitro and in OLGs, to help identify the 
mechanism.  Analysis of in vitro translation of Venus-MBP mRNA in wheat germ lysate in the 
presence and absence of exogenous TOG would be useful in assessing TOG’s role in 
translation of MBP mRNA.  Differences in translation in the presence of exogenous TOG would 
suggest that TOG may have a role independent of involvement in cell signaling, independent of 
its role of as a microtubule binding protein, and independent of TOG’s ability to affect MBP 
mRNA localization.  One such mechanism that has been proposed is that TOG may promote 
translation by blocking the binding of the translational inhibitor hnRNP E1 to hnRNP A2 and/or 
by preventing the binding of another potential translational inhibitor TACC to CPEB on MBP 
mRNA (Francone et al., 2007).   It has also been suggested that TOG binding to hnRNP A2 
may prevent hnRNP A2 from inhibiting protein phosphatase 2A (PP2A).  PP2A is responsible 
for dephosphorylating the elongation factor eEF2, which is in its active form when 
dephosphorylated (Francone et al., 2007).  If TOG works through those mechanisms then 
differences in in vitro translation of MBP mRNA may be detected when TOG is present in the 
wheat germ lysate.  This is of course contingent on the presence of those regulators in wheat 
germ lysate, which would first have to be assessed.  If they were not present, assays in which 
they are added to the wheat germ lysate could be performed to investigate TOG’s influence on 
their regulation of MBP mRNA translation.   
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Assays in OLGs 
Analysis of OLGs in which TOG was knocked down using shRNA, showed no differences in 
MBP mRNA granule formation and localization (Francone et al., 2007).  However, examination 
of neurons in which TOG was knocked out showed decreased numbers and decreased size of 
Arc RNA containing granules in dendrites (Barbarese et al., 2013).  In situ hybridization should 
be performed in CNP TOG cKO OLGs to reveal if MBP mRNA granule assembly and/or 
transport are altered in the absence of TOG. 
Work on the A2RE containing Arc mRNA in neurons implies that TOG is involved in polysomal 
translation of A2RE containing mRNAs (Barbarese et al., 2013).   However, TOG is thought to 
associate with MBP mRNA through hnRNP A2, which is believed to be released from binding 
with MBP mRNA prior to the start of translation.  Future work should further investigate TOG’s 
role in polysomal translation of MBP mRNA.  A polysome profile examining if TOG associated 
with polysomes in control OLGs would be helpful in determining if TOG itself associates with 
translationally active mRNA.  In addition, polysome profiling of MBP mRNA in the brain of 
control and CNP TOG cKO would help determine if indeed TOG promotes polysomal translation 
in OLGs.  If TOG is involved in promoting polysomal translation then a smaller percentage of 
MBP mRNA should be found associated with polyribosomes in the CNP TOG cKO than in 
controls.   
The mechanism by which TOG influences translation of MBP mRNA in OLGs can further be 
investigated in several ways.  Phosphorylation of hnRNP A2 by fyn kinase is believed to 
stimulate MBP mRNA translation in OLGs (White et al., 2008).   TOG’s role in this 
phosphorylation event could be determined by analyzing the phosphorylation of hnRNP A2 in 
the corpus callosum of the CNP TOG cKO, the TOG heterozygote, and in rat OLG cultures in 
which TOG has been knocked down.  The mechanisms proposed by Francone et al. (2007), 
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and discussed in the previous paragraph on in vitro assays, could also be analyzed in cultured 
OLGs with reduced levels of TOG or in homogenate from the corpus callosum of the TOG CNP 
cKO. 
Investigating TOG’s regulation in OLGs 
TOG has a very important function in MBP expression, yet very little is known about TOG in 
OLGs in both normal and diseased states.  Further analysis of TOG in OLGs should be 
performed.  Examining if TOG levels or the phosphorylation of TOG changes depending on the 
stage of the OLG would provide insight as to whether TOG expression or phosphorylation of 
TOG correlate with MBP expression in any way.  In addition, little is known on what can alter 
TOG expression in OLGs.  It has been shown that the microRNA miR-155 can decrease TOG 
expression and that miR-155 is upregulated in multiple sclerosis (Junker et al., 2009).  
Investigation of TOG levels in OLGs of individuals affected with multiple sclerosis or mice 
subjected to experimental autoimmune encephalitis (EAE), a model used for multiple sclerosis, 
would provide crucial information on TOG regulation in OLGs and its possible role in multiple 
sclerosis.   
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